

AUTHOR INDEX

- Aboud, P., 326, 1792
 Abella, S., 546
 Aberg, J. A., 124
 Abraham, O. C., 546
 Abter, E. L., e100
 Acar, J., S156
 Accordini, A., e143
 Acheson, D. W. K., 1517
 Adachi, J. A., 1706
 Adle-Biassette, H., 1371
 Adler-Klein, D., 352
 Adult and Adolescent Spectrum of HIV Disease Project, 794
 Agematsu, K., 1399, 1408
 Aguero-Rosenfeld, M. E., 862
 Ahmad, H., e100
 Ahn, K.-M., 1463
 AIDS Clinical Trials Group, 1615
 Akgün, Y., e59
 Akiyama, H., 1325
 Al-Abdely, H., 50
 Alagaratnam, M., 1691
 Alaimo, C., 1126
 Alam, A., 884
 Alangaden, G. J., 313, 546
 Al-Awar, G., 820
 Alberici, F., 638
 Alberio, L., 1338
 Albert, M. J., 884
 Allegra, L., 1281
 Allen, J. E., 1378
 Allos, B. M., 1201
 Almirante, B., 1024
 Almuneef, M. A., 220
 Alonso, P., 970
 al-Ramadi, B., e87
 Alvarez-Olmos, M. I., 1567
 Amábil-Cuevas, C. F., S30
 Anaisse, E. J., 1713
 Anargyrou, K., 1718
 Andersson, B. S., e94
 Andre, M., 44
 Andremont, A., 1393
 Andres, A., 17
 Andrews, M.-M., 1470
 Anekthananon, T., 483
 Añel, R. M. L., e131
 Anguita, M. L., 17
 Anis, A. H., 1685
 Anstead, G. M., 295
 Antique, J., 1117
 Aplasca de los Reyes, M. R., 1313
 Apolinario, I. S., 808
 Appelbaum, P. C., 1463
 Apperley, J. F., 413
 Arashima, Y., 989
 Arend, S. M., 323
 Arevalo, J., 808
 Arista, S., 1126
 Ariza, J., 1024
 Arjoso, S., 1039
 Arlet, G., 1776
 Armstrong, W. S., 766
 Arrowood, M. J., 1010
 Artola, V., e105
 Arvilommi, H., 1577
 Asaad, R., 1487
 Asciglu, S., 1713
 Ashford, D. A., e78
 Ashkin, D., 323, 515
 Assmann, S. F., 116
 Aswapeokee, N., 1463
 Attorri, S., 1511
 Auleta, I. J., 9
 Avery, R. K., 1656
 Azoulay, E., 30
 Babcock, H. M., 1373
 Babl, F. E., 1155
 Baccus-Taylor, G., 890
 Bachmann, S., 842
 Backenroth, R., 1502
 Baddley, J. W., 1319
 Baddour, L. M., e17
 Badri, S. M., 826
 Baer, E. T., 991
 Bahrami, A., 1231
 Bailey, A. M., e151
 Baker, C. J., 1018
 Baker, D. K., 36
 Baker, I., 1784
 Bakken, J. S., 862
 Balasubramanyam, A., 153
 Baldwin, M. S., 1010
 Ball, P., S72
 Ball, R., 1273
 Ballas, K., e111
 Ballet, J. J., 1792
 Baltimore, R. S., 220
 Baluch, M., 862
 Bamberger, D. M., 1215
 Banerjee, D., 396
 Bange, F.-C., 1648
 Bani-Sadr, F., 963
 Banuls, A.-L., 302
 Baquero, F., 1298
 Baran, J., Jr., 1381
 Barboteu, M., 30
 Barlow, G., 728
 Barnett, E. D., 1004
 Baron, E. J., 605
 Barry, M., 1470
 Barth, A., S133
 Bartlett, S., 1623
 Barton, T. D., 391
 Barza, M., 1
 Basara, N., e1
 Basgoz, N., 130
 Bates, D. W., 686
 Baughn, R. E., 534
 Baynes, R., 546
 Beach, M., S114
 Beato, J. L., 506
 Beatrice, S. T., 1227
 Becerril, B., 587
 Becker, K., 1643
 Becker, S., 1615
 Beguinot, I., 1494
 Beinker, N., 1487
 Belkengren, R. P., 694
 Bell, J., S114
 Belongia, E. A., 1434
 Benčina, D., e31
 Benpal, T., 469
 Ben-Haim, M., 822
 Bennish, M. L., 331
 Benoit, C., 1776
 Benson, C. A., 815, 1615
 Bentley, G., 313
 Bentley, M., 476
 Beqaj, S., 1657
 Berbers, G. A. M., 2
 Berkhamer, S., 1090
 Bernabeu, M., 587
 Berning, S. E., 643
 Bersoff-Matcha, S. J., 124
 Bethell, D. B., 243
 Beveridge, R. A., 381
 Bevilacqua, S., 1494
 Bica, I., 492
 Bier, J. W., 1010
 Biliková, E., 1110
 Bilker, W. B., 1162
 Binkin, N. J., 373
 Bischoff, M., e1
 Bishara, J., e176
 Bitnun, A., 1674
 Blaser, M. J., 295
 Blasi, F., 1281
 Blau, I. W., e1
 Blockmans, D., 191
 Blot, F., e92
 Blumberg, E. A., 307
 Blumer, J. L., 381
 Bobbaers, H., 191
 Bodey, G. P., e145
 Boeckh, M., 214, 321
 Bogdan, C., 302
 Bonsu, B. K., 566
 Bordigoni, P., 1290
 Borkowsky, W., 801
 Bornstain, C., 30
 Borock, E., 1090
 Borsa-Lebas, F., 1792
 Bossi, C., e143
 Böttger, E. C., 1648
 Boudjemaa, H., 830
 Braconier, J.H., 1523
 Braggion, C., e15
 Brasseur, P., 1792
 Braun, M. M., 1273
 Brazer, S., 975
 Breiman, R. F., 283
 Breukels, M. A., 1700
 Bridges, C. B., 1784
 Brinkman, K., 1095
 Britigan, B. E., 255
 Broadhead, R., 1496
 Brown, B. A., 1547, 1648
 Brown, C., 890
 Brown, P., 1221
 Brozena, S. C., 307
 Brugieres, P., 1371
 Brun-Buisson, C., e92, 877
 Bruneel, E., 1133
 Brunori, M., 1414
 Burke, G., 662
 Burman, W. J., 836
 Bush, K., 1085
 Bybel, M., 170
 Caballero-Granado, F. J., 587
 Cabrera, C. E., 855
 Cacoub, P., 1207
 Cadrel, J.-F., 830
 Calderon, M., 808
 Cammarata, S. K., 402
 Canaple, S., e154
 Cañas, C., 1024
 Canas, L. C., 1639
 Cantón, P., 1494
 Cantón, R., S94, 1298
 Canzonieri, V., 1100
 Caramico, L., e111
 Carbone, A., 1100
 Carling, P. C., 1519
 Carlos, C. C., 1463
 Carlson, C., 983
 Carmeli, Y., 1055
 Carmoī, T., 991
 Caro, P., 17
 Caron, C., 830
 Caron, F., 326, 1792
 Carosi, G., 1063
 Carret, A.-S., 1290
 Casadevall, A., 670
 Casanova, A., 1024
 Cascio, A., 1126
 Casellas, J.-M., S94
 Cassells, L., 546
 Castagnola, E., 1532
 Cazier, A., 830
 Cazzola, G., e15
 Celum, C. L., 611
 Chalasani, G., 546
 Chambers, H. E., 521
 Champlin, R. E., 871
 Chan, E. D., 1506
 Chan, P. K. S., 1376
 Chan, R. M. T., 701
 Chandenier, J., e154
 Chandrasekar, P. H., 313, 320,
 546
 Chang, C. H., 1657
 Chang, Y. J., 1104
 Chapnick, E. K., e100
 Chappell, C. L., 1516
 Chariyalertsak, S., 955
 Charrois, A., 297
 Chaturvedi, V., 1034
 Chau, T. T. H., 243

- Chavez, V. M., 808
 Chen, G., 534
 Chen, K., 170
 Chen, M.-Y., 1361
 Chen, Q., 1325
 Cheng, A. F., 1376
 Cheng, V. C. C., 701, 846
 Cherian, T., 1463
 Cherry, T. A., 643
 Chertow, G. M., 686
 Chesney, M., 476
 Cheung, J. L. K., 1376
 Chevalier, B., 991
 Chevret, S., 30
 Chiphangwi, J. D., 1496
 Chiu, C.-H., 520, 1463
 Chiwakata, C. B., 144
 Choi, E.-H., 1423
 Chongthaleong, A., 1463
 Choo, P. W., 140
 Chow, A. W., 381
 Chowdhry, T. K., 1487
 Christiansen, E., 1373
 Chuang, E. L., 214
 Ciancio, G., 662
 Cisneros, J. M., 587
 Ciufolini, M. G., 1241
 Claiborne, C. V., 502
 Clarridge, J. E., III, 1511
 Cloud, G., 1215
 Cockerill, F. R., III, 1540
 Cohen, D. E., 1756
 Cohen, M. S., 255
 Cohen, Y., e176
 Cohn, D. L., 623
 Cohn, W. E., e120
 Colby, T. V., 1448
 Coldsmith, E. E., 938
 Collier, A. C., 116
 Collis, T. K., 391, 611
 Colson, A. E., 140
 Comissiong, E., 890
 Connick, E., 1623
 Connor, B. A., 396
 Coons, S. J., e47
 Corcoran, C., 130
 Corey, G. R., 647, 975
 Corey, L., 214
 Corredoira, J. M., 1024
 Corresponding Group, 1133
 Corvatta, L., 1414
 Couch, L. A., 1547
 Coutarel, P., 830
 Craft, J. C., 1798
 Craig, F. E., 295
 Crane, L., 1221
 Craven, D. E., 1249
 Crawford, S., e140
 Crippa, F., 214
 Cron, S. G., 1516
 Cuberos, L., 587
 Culotta, A., 808
 Cumsille, F., 855
 Cunha, B. A., 671
 Cunningham, C. K., 801
 Currier, J. S., 1615
 Cusi, M. G., 1241
 Cu-Uvin, S., 476
 Czachor, J. S., e53
 D'Agata, E. M. C., 23
 D'Agostino, R. B., 130
 Dalhoff, A., S16, S22
 Dallabetta, G., 1313
 Daniels, N., 890
 Danilovitsh, M., 373
 Danis, M., e154, 1133
 Danner, S. A., e81
 Dansey, R., 546
 D'Aquila, R. T., 774
 Darmon, M., 30
 Dasbach, E. J., 686
 da Silva, A. J., 1010
 Davey, P., 728
 Davidson, R., 1487
 Davis, B., 130
 Davis, L. E., 979
 Davis, S., 236
 Davis, T., 1487
 Day, N. P. J., 243
 De Boeck, K., e62
 De Caestecker, J., 191
 De Clercq, E., e62
 De Dobbeleer, G., e9
 Deeter, R. G., 1657
 De Guzman, A. M., 1784
 Dekumyo, P., e154
 de la Brassine, M., e9
 Delacour, T., 830
 Delamare, C., 297
 Delangle, M. H., 162
 Delate, T., e47
 Delgado, J., 633
 de Maubeuge, J., e9
 Dembry, L. M., 220
 de Melker, H. E., 2
 de Metz, J., e81
 Denic, L., 1393
 Denis, F., 197
 Denning, E., 623
 de Oliveira Macêdo, V., 1304
 Derdelinckx, I., e9
 Desachy, A., 197
 de Tomas, E., 506
 De Witt, C. C., 1639
 Dhar, R., 492
 Diaz, P. S., 694
 Dick, J. D., e36
 Didier, J., 30
 Diekema, D. J., S114
 Dietrich, M., 144
 di Gennaro, G., 1100
 Dik, H., 323
 Di Martino, V., 830
 Dionisio, D., 1241
 DiPersio, J. R., 1562
 DiPersio, L. P., 1562
 Dismukes, W. E., 255, 518
 Dlugos, D. J., 173
 Dodek, P. M., 1685
 Dodson, D. R., 1010
 Doern, G. V., S81
 Dolan, D. M., 1639
 Dolan, M. J., 1639
 Doney, A., 1034
 Dorvaux, V., 1494
 Douard, M. C., 1776
 Doucette, K., 1500
 Dovč, P., e31
 Dowdy, L., 662
 Dowell, S. F., 824
 Drachenberg, C., 167
 Duim, B., e97
 Duliege, A. M., 801
 Dumler, J. S., 862
 Dumot, J., 1656
 Dumouchel, P., 830
 Dunbar, S., 1511
 Dung, N. M., 243
 Dung, N. T., e78
 Duong, N. M., e78
 DuPont, H., 331, 1706
 Dutta, D. K., 884
 Dworkin, H., 1657
 Dworkin, M. S., 794
 Dwyer, A. P., 1506
 Dylewski, J., 1112
 Eberhard, M. L., 1010, 1378
 Ebright, J. R., e90
 Eby, G. A., 1520
 Edelman, L., 667
 Edelstein, P. H., 1162
 Edlund, C., 1384
 Edmond, M. B., 1538
 Edwards, J. E., Jr., 76, 518, 1110
 Edwards, K. M., 847, 1698
 Egger, M., 995
 Elgart, L., 1366
 Elizaga, J., 413
 Ellis, M. E., 50, e87
 El-Sadr, W. M., 623
 Elsen, C., 1090
 Elta, G., 983
 Elting, L., 871
 Embil, J. M., 636, 1500
 Emery, K. W., 708
 Emery, V. C., 1357
 Englund, J., 1090
 Enting, R. H., 1095
 Epstein, D., 559
 Erdman, D. D., 694
 Ericsson, C. D., 1706
 Eriksson, B. K. G., e24
 Escobar, H., 1298
 Estmon, C. T., 1338
 Espaze, E., 162
 Esperti, F., 1241
 Esposito, S., 1281
 Esteve, A., 159
 Estey, E., 539
 Etienne, J., 1440
 Etienne, M., 326
 Fabregat, J., 1024
 Faccini, M., e143
 Fang, C.-T., 1361
 Faris-Young, S., 167
 Farr, B. M., 1249
 Farrar, J., 204
 Farrel, P. A., 220
 Fauci, A. S., 675
 Fauser, A. A., e1
 Favenec, L., 1792
 Feddersen, R. M., 300
 Feenstra, L., e62
 Feinberg, J., 1615
 Feld, R., 381
 Fennelly, K., 1506
 Fenton, T., 801
 Fernandez, M., 1018
 Ferraz, V., 289
 Fichtenbaum, C., 1615
 Fierer, J., 519
 File, T. M., Jr., 1562
 Filler, S. G., 518
 Fine, A., 277, 1784
 Finkel, M. F., 1434
 Fisher, D., e102
 Fishman, N. O., 1162
 Fisman, D. N., 419
 Fitzgerald, T., 1657
 Flagg, S. D., 1104
 Flanigan, T. P., 116
 Fleer, A., e97
 Fleisch, F., 581
 Fleisher, A. S., 502
 Fleisher, G. R., 1004
 Fleming, T., 476
 Fluit, A. C., S81
 Flynn, P. M., 36, 1456
 Foley, K. M., 1331
 Fonquerne, L., 297
 Ford, G., 842
 Ford-Jones, E. L., 1674
 Forgacs, P., 179
 Forman, M. S., e13
 Forrest, D. M., 1685
 Forward, K. R., S104
 Foster, C. L., 367
 Fournier, P.-E., 1440
 Fowler, V. G., Jr., 647
 Francis, D., 801
 Franco, C., 1103
 François, B., 197
 Fraser, V. J., 1331
 Frederiksen, W., 987
 Freedberg, K. A., 783
 Freedman, D. O., 757
 Freidberg, S. R., 179
 French, M. A., 325
 French, P., 660
 Friddkin, S. K., 108
 Friedlaender, M. M., 1502
 Froeschle, J. E., 170
 Frottier, J., 297
 Fujita, K., e22
 Fukuda, K., 1784
 Fullem, A., 476
 Gabay, B., e176
 Gachot, B., 1133
 Gaillon, S., 1393
 Gajewski, J., 871
 Gales, A. C., S104, S146
 Gamble, J., 243
 Gantz, N. M., 938
 Garcia-Diaz, J. B., e166

- Gargala, G., 1792
 Garman, R. L., 824
 Gartside, I. B., 243
 Gassin, M., 963
 Gastinne, H., 197
 Gaur, A. H., 1456
 Gazzard, B. G., 469
 Geddie, Y. A., 1639
 Geelen, S. P. M., e97
 Geffray, L., 1207
 Gennings, C., 1538
 George, J., 170
 Gerber, S. I., 694
 Gershman, K., e151
 Gessain, A., 510
 Gessner, B. D., 1039
 Geyer, C. A., 179
 Ghosh, S., 539
 Giamarellos-Bourboulis, E. J., 1718
 Giamarellou, H., 1718
 Gibbard, W. B., 1637
 Gigliotti, F., 855
 Gill, J., 469
 Gilliland, K. K., S39
 Gilman, R. H., 808
 Gilroy, C. B., 995
 Giralt, S., 871
 Girard, W. M., 1547
 Giry, P., 1393
 Gitlin, S. D., 983
 Glatt, A. E., 752
 Gläuser, M., 1532
 Glover, L., 1784
 Gluckman, S. J., 505
 Golden, M. P., 1366
 Goldie, S. J., 419, 783
 Goldman, J. M., 413
 Goldstein, J., 1657
 Goldstein, L. J., 970
 Gomes, D. R. J., 686
 Gómez Paes, M., 1304
 Gómez-Mampaso, E., 1298
 Gomez-Pastrana, D., 17
 Gondry-Jouet, C., e154
 González, J. M., e158
 Gooch, W. M., III, 1798
 Googe, P. B., e17
 Gorbach, S. L., 1
 Gorka, W., e87
 Gottehrer, N. P., 559
 Gout, O., 510
 Grace, C. J., 1651
 Graham, D. Y., 1387
 Graninger, W., 838
 Grant, B., 352
 Grecka, P., 1718
 Green, W. K., 23
 Greenberg, P. D., 1117
 Greer, W., 50
 Griffin, P. M., 331
 Griffith, B. E., 1547
 Griffith, D. E., 432, 1547
 Grinspoon, S., 130
 Gripshover, B. M., 1487
 Grossman, R., 436
- Grulich, A. E., 989
 Grupo de Estudio de Castilla la Mancha de Enfermedades Infecciosas Group, 506
 Guarner, J., 1448
 Gucalp, R., 381
 Gueit, I., 326
 Guerrant, R. L., 331
 Gülbas, Z., e59
 Gumbo, T., 1235
 Günther, S., 144
 Günzelmann, S., e1
 Gurland, I. A., 667
 Gutiérrez, F., 149
 Habib, G., 1440
 Hachem, R., 186
 Haddad, M. C., 820
 Hadigan, C., 130
 Hadler, S. C., 522
 Hajjeh, R. A., e151, 708, 1110, 1215, 1448
 Hakim, J. G., 1235
 Halperin, S. A., 1691
 Hamilton, J. D., 605
 Hamor, R., 1562
 Hamrick, H. J., Jr., 124
 Han, X. Y., e145
 Hanauer, S. D., 1010
 Hanf-Kristufek, L., 990
 Hanna, G. J., 774
 Hannah, E. L., e151
 Hannoun, C., 144
 Hanson, D. L., 794
 Harle, J.-R., 1440
 Harper, M. B., 566
 Harrell, C. C., 990
 Harris, A. D., 317, 1055
 Harris, J. A. S., 1249
 Hart, S. M., 1430
 Harwell, J. I., e102
 Hatcher, J. C., 1117
 Hathorn, J. W., 381
 Hawkins, E., 801
 Hayden, M. K., 826
 Hebert, J., 1511
 Hedderwick, S. A., 367
 Heenen, M., e9
 Heiskanen, L., 1141
 Heiss, M., 832
 Helft, J., 1108
 Hemsel, D. L., 103
 Henderson, H., 1215
 Hendrickx, L., 527
 Hennequin, C., e154
 Hennessy, T., 331
 Henriques Normark, B., 552
 Herbich, K., 838
 Herchline, T. E., e53
 Hermann, G., 1104
 Hermida-Escobedo, C., S30
 Herwaldt, B. L., 1010
 Hetherington, S. V., 36
 Heurter, H., 1674
 Hewitt, R. G., 1517
 Heyman, W., 505
 Hidalgo, A. M., 149
- Hide, M., 302
 Hien, T. V., e78
 Higgs, E. S., 1517
 Himmelman, A., 1233
 Hisada, M., 515
 Ho, P. L., 701
 Ho, W. G., 381
 Hoa, N. T. T., e78
 Hoban, D. J., S81
 Hockmann, J., 1643
 Hoff, J., 963
 Hoffman, R. E., e151
 Hoffman, T., 662
 Hoffner, S. E., 373
 Hohmann, E. L., 263
 Hollender, E. S., 323, 515
 Holloway, M., 1215
 Holmes, K. K., 1313
 Holtz, T. H., e124
 Hong, J.-Y., 1423
 Hooper, D. C., S9
 Horn, R., 381
 Horner, P., 995
 Hornick, R., 396
 Horowitz, H. W., 862
 Hospedales, J., 890
 Hota, B., 826
 Hotez, P. J., e111
 Houston, S., 150
 Hsieh, S.-M., 1361
 Hudson, M. M., 36
 Hughes, W. T., 36, 855
 Hung, C.-C., 1361
 Hunter, P. R., 1795
 Huovinen, P., 1608
 Hurst, L., 1500
 Hurwitz, S., 44
 Husson, J., e154
 Hutchins, G. M., e36
 Iannini, P. B., 1112
 Ibrahim, E., 515
 Idigoras, P., e158
 Indar-Harrinauth, L., 890
 Infectious Diseases Society of America, 604
 Ing, M. B., e39
 Inglesby, T. V., 436
 Inoue, T., 1325
 International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer, 1532
 International-Infectious Disease Society for Obstetrics and Gynecology-USA, 103
 Iseman, M. D., 643, 1506
 Ismail, A., 1235
 Itakura, O., e57
 Jacobs, M. R., 1463
 Jacobson, K., 539, 871
 Jacquot, S., 326
 Jamal, F., 1463
 Jazbec, J., e31
 Jenkins, J., e124
 Jenny-Avital, E. R., 322, 1227
- Jensen, E., 396
 Jiang, Z.-D., 1706
 Jie, C., 650
 Jimenez-Lucho, V. E., 1117
 John, C. C., 9
 Johnson, D., 1090
 Johnson, D. W., 815
 Johnson, G., 1674
 Johnson, R., 708
 Johnson, R. M., 1628
 Johnson, S. C., 815
 Johnson, W. D., 255
 Joiner, K., 255, 755
 Joint Study Group on Hepatitis C Virus of the French National Society of Internal Medicine and the French Society of Infectious Diseases (GERMIVIC Study Group), 1207
 Jokinen, C., 1141
 Jones, B., 662
 Jones, J. L., 794
 Jones, R. C., 694
 Jones, R. N., S81, S104, S114, S133, S146, S156
 Jorgensen, J. H., e140, 295
 Juffermans, N. P., 650
 Jurado, R., 1103
 Jurriaans, S., 1095
 Just-Nübling, G., 1235
 Juvonen, H., 1141
 Kachur, S. P., e124
 Kajon, A. E., 694
 Källenius, G., 552
 Kallinen, S., 1141
 Kang, M., 801
 Kanno, M., 313
 Kantarjian, H., 539
 Kao, A., 708
 Kaplan, E. L., 1798
 Kaplan, J. E., 794
 Karanés, C., 546
 Karchmer, A. W., 255, 419
 Karchmer, T. B., 1055
 Kato, K., 989
 Kato-Maeda, M., 1580
 Katsilambros, N., 1718
 Katti, M. K., 1114
 Kauffman, C. A., 367, 1215
 Kawakami, Y., 1399, 1408
 Kawano, K., 989
 Kazanjian, P., 766
 Kazmierczak, J. J., 1434
 Kedlaya, I., e39
 Kelen, G. D., 655
 Keller, M. J., 140
 Keller, N., S133
 Keravel, Y., 1371
 Kern, W. V., 832
 Kessler, H. A., 1635
 Ketai, L., 300
 Keystone, J. S., 757
 Khan, M. Y., 1172
 Khan, S. A., 884
 Khatib, R., 1381
 Kiehl, M. G., e1

- Kiehn, T. E., 1034
 Kikuchi, K., 1399, 1408
 Kikuta, H., e57
 Kim, S., 1463
 Kim, W.-S., 1423
 Kimmel, A. D., 783
 King, S., 1685, 1554
 Kiraz, N., e59
 Kirsch, M., 877
 Kirsten, D., e1
 Kish, M. A., 851
 Kitamura, T., 1325
 Klastersky, J., 1532
 Klausner, J. D., 1313
 Kleemola, M., 1141
 Klein, J., 546
 Klein, J. O., 1155
 Klosters, G., 311
 Kneen, R., 204
 Knockaert, D., 191
 Knox, T. A., 1769
 Kobayashi, K., e57
 Koehler, J. E., e124
 Koh, Y.-Y., 1423
 Kok, R. H. J., 311
 Komatsu, K. K., 1448
 Kong, P.-M., 1506
 Konoplev, S., 539
 Kontoyannis, D., e94, e145, 871
 Korn, L., 667
 Koskela, M., 1141
 Kovačičová, G., 1110
 Kozarsky, P. E., 757
 Krasemann, C. S22, S51
 Krčmery, V., 1110, 1656
 Kremsner, P. G., 838
 Krubel, S., 116
 Kruunier, A., 373
 Kubin, R., 1112
 Kubitzka, D., S47
 Kubota, M., e57
 Kularatne, R., 289
 Kumar, P. N., 116
 Kumadasaka, K., 989
 Kumwenda, N., 1496
 Kuppermann, N., 1004
 Kurosu, T., 1325
 Kuster, R. L., 1010
 Kuter, B., 396
 Kwok, T. K., 701
 Lalitha, M. K., 1463
 Lämmle, B., 1338
 Lamoste, T. J., e100
 Lancaster, D., 1215
 Landman, D., 1245
 Lane, H. C., 1738
 Lane, J. E., e107
 Lange, J. M. A., 1095
 Lapin, R. H., 1518
 La Rosa, A. M., 871
 la Rosa, R., 633
 Larruskain, J., e158
 Larsen, B., e69
 Laurel, V. L., 1639
 Lautenbach, E., 1162
 Lauw, F. N., e81
 Law, M. G., 989
 Layton, M., 277
 Lazarus, H. M., 381
 Leal, M., 633
 Lechi, A., e143
 Lederman, H. M., e13
 Lederman, M. M., 1487
 Ledger, W. J., 103
 Lee, H.-J., 1423
 Lee, N. Y., 1463
 Lee, S.-I., 1463
 Le Faou, A., 1290
 Legakis, N., S94
 Le Gall, J.-R., 30
 Leighton, J. A., 1448
 Leinonen, M., 1141
 Lell, B., 838
 Lemée, V., 1792
 Leoni, P., 1414
 Leport, C., 1776
 Lerner, A. M., 1657
 Lesprit, P., 1371
 Levina, K., 373
 Levine, B., 1244
 Levine, O. S., 824
 Lewis, R. E., e94
 Li, H., 23
 Li, J., 1463
 Lianc, M., 1371
 Lieberman, J., 1651
 Liedtke, L. A., 270
 Lillehoj, E., 842
 Lin, S.-J., 358
 Lin, T.-Y., 1463
 Lihares, J., S104
 Lindsley, M., e151, 1448
 Linezolid Nosocomial Pneumonia Study Group, 402
 Lipsitch, M., 1044
 Lisbon, A., e120
 Lissen, E., 633
 Lister, P. D., S33
 Littenberg, B., 1651
 Little, R., 1373, 1628
 Liu, G., 824
 Liu, G. T., 173
 Livingood, W. C., 170
 Loan, H. T., 243
 Loc, P. P., e78, 243
 Lockman, S., 373
 Logan, N. D., 1387
 Loisance, D., 877
 Long, H. Y., 838
 Longhurst, C. A., 1659
 Longuet, P., 1776
 Lopez, A. S., 1010
 López, F., 149
 Lopez, F. A., 1430
 López-Barrio, A. M., 17
 López-Lopategui, M. C., e158
 Lorente, C. A., 1378
 Lorenz, E., 302
 Losina, E., 783
 Louie, T. J., 381
 Low, D. E., S133
 Lubritz, G., 1643
 Lucet, J.-C., 1393
 Luckner, D., 838
 Lugoboni, F., e143
 Luna, M., 539
 Lund, B., 1384
 Lundstrom, T., 1602
 Lupi, C., 1241
 Lyke, K. E., 1178
 Lyon, G. M., 1448
 MacArthur, J. R., e124
 MacGregor, D., 1674
 Macías, J., 633
 MacKnight, C., 1726
 Maes, A., 191
 Maestre, A., 149
 Magnusson, M., 1523
 Mah, M. W., 1172
 Maiwald, M., 457
 Maiz, L., 1298
 Mäkelä, P. H., 1141
 Malaty, H. M., 1387
 Malley, R., 1004
 Mamikoğlu, L., 1658
 Manalastas, R., 1313
 Mandell, G. L., 255
 Mandell, L. A., S72
 Manegold, C., 144
 Manning, W. J., e120
 Marchi, A., 1241
 Mariuz, P. R., 483
 Markovitz, D. M., 983
 Márquez, M., 159
 Marr, K., 321
 Marrón, A., 1024
 Martens, M., 103
 Martín, C., 159
 Martínez, F., 1024
 Martínez-Alfaro, E., 506
 Martínez-Sandoval, F., 1706
 Martino, P., 1532
 Martín-Sánchez, J., 633
 Marty, F., 1108
 Maruchi, N., 1399, 1408
 Mashinter, L., 150
 Massung, R. F., 979
 Masuell, C. P., 1104
 Mathewson, J. J., 1706
 Matsumoto, A. K., 502
 Matteelli, A., 1063
 Matts, J. P., 623
 Matushek, M., 826
 May, T., 1494
 Mayer, K. H., 476
 Mayxay, M., 653
 Mazzoli, F., 1241
 McCormsey, G., 1487
 McCullers, J. A., 1456
 McElmeel, M. L., e140
 McEniry, D., 396
 McFarland, E. J., 801
 McGeer, A., 1554
 McGovern, B., 492
 McGowan, K., 492
 McKechnie, D. B., 979
 McLeod, G. X., 352
 McMinn, P., 236
 McNamara, J., 801
 McNeil, M. M., e78
 McNeil, S. A., 367
 Mecereno, V., e143
 Mediawala, R., 534
 Mehta, S. D., 655
 Meigs, J. B., 130
 Meissner, H. C., 1004
 Mekontso-Dessap, A., 877
 Mele, A., 1414
 Memish, Z. A., 1172
 Mendelson, M. H., 1104
 Mermel, L. A., 1249
 Mertens, R., 302
 Merz, W. G., 1178
 Meschievitz, C., 170
 Metze, D., 1643
 Meyer, J., S51
 Meynard, J. L., 297
 Meyohas, M. C., 297
 Mezzelani, P., e143
 Michael, J. R., 498
 Mielke, J., 1235
 Mies, C., 662
 Mikol, J., 510
 Miller, D. L., 975
 Miller, J., 662
 Miller, J. M., 605
 Miller, L. G., 1110
 Miller, N. S., 1178
 Miller, W. C., 124
 Minari, A., 186
 Miotti, P. G., 1496
 Mirete, C., 149
 Mirza, N., 871
 Mitchell, P. D., 1434
 Moench, T., 476
 Mofenson, L., 801
 Molina, J. M., 1776
 Monif, G. R. G., e69, 103
 Monira, S., 884
 Monmeneu, J. V., 149
 Montanari, M., 1414
 Moore, C. C., e107
 Moore, D. A. J., 469
 Moore, G., 44
 Moore, T., e122
 Mootrey, G. T., 1273
 Mora, A., 149
 Moran, G. J., 573
 Mori, S.-i., 1325
 Morillas, F., 633
 Morris, A., 1691
 Morris, A. J., 647
 Mortelmans, L., 191
 Moschella, S. L., 930
 Mousharafieh, U., 820
 Mower, W. R., 573
 Mowgli Study Group, 1281
 Moylett, E. H., 1018
 Mtimavalye, L., 1496
 Mueller-Rizner, N., 1434
 Mundy, L. M., 124
 Murdoch, D., 647, 975
 Murphy, E. L., 116
 Murray, C. K., e140

- Murray, K. A., 498
 Musher, D. M., 307, 534, 1511
 Nace, E. M., 1010
 Nachamkin, I., 331
 Naeyaert, J.-M., e9
 Nagarajan, L., 236
 Nahar, S., 884
 Nahum, R., 1371
 Nájera, R., 1732
 Nakama, H., 1399, 1408
 Nakamura, T., 1399, 1408
 Nakamura-Uchiyama, F., e171
 Nakase, J. Y., 573
 Narita, M., 323, 515
 Nasti, G., 1100
 Natarajan, S., 1104
 Nathwani, D., 728
 National Institute of Allergy and Infectious Diseases Mycoses Study Group, 1215
 Navarro, J., 17
 Nawa, Y., e171
 Neill, M., 331
 Nelson, C., 1039
 Nelson, K. E., 955
 Nelson, S., 1674
 Nerad, J. L., 1635
 Nessa, K., 884
 Neuville, S., 30
 Neuzil, K. M., 847
 Newdow, M., 573
 Newell, J. P., e124
 Newton, P., 653
 Ng, T. K., 701
 Nga, N. T. T., 204
 Nguyen, Q., 539
 Nhan, N. T., 204
 Norgren, M., e24
 Normark, S., 552
 Notario, G. F., 1798
 Novak, R., 552
 Nowak-Wegrzyn, A., e13
 Noyola, D. E., 1018
 Oberhelman, R. A., 1567
 Offidani, M., 1414
 Ofotokun, I., 983
 O'Grady, N., 1249
 Ohashi, K., 1325
 Okamura, A., e57
 Olavarria, E., 413
 Oldfield, E. C., III, 1231
 Oliphant, T. H., 402
 Oliver, A., 1298
 Olivieri, A., 1414
 Olsen, K. M., e83
 Oltman, S., 1010
 Onah, D. N., e171
 O'Neill, W., 1657
 Ong, S., 573
 Onozawa, Y., 1325
 Ooi, W. W., 930
 Orlandi, P. A., Jr., 1010
 Orlovic, D., 44, 289
 Ormerod, L. D., 1661
 Ortqvist, Å., 552
 Osborne, N. G., 103
- Osterholm, M. T., 331
 O'Toole, T., 436
 Otto, G., 1523
 Ou, J. T., 520
 Owens, S., 1615
 Ozden, S., 510
 Pachón, J., 587
 Paesmans, M., 1532
 Pahissa, A., 1024
 Paladino, J. A., S39
 Palatnick, W., 636
 Palau, L., e166
 Paltiel, A. D., 783
 Pani, A., e143
 Pankey, G. A., e166
 Pantalena, M., e143
 Pappas, P. G., 518, 1215, 1319
 Parent, E. M., 1470
 Parise, M. E., e124
 Park, K.-H., 1423
 Park, S., 1034
 Parola, P., 897
 Parry, M. F., 352, 1245
 Parsonnet, J., 1470
 Pasha, T. M., 1448
 Patel, J. B., 1162
 Patel, R., 1540
 Pato-Mesola, V., 1313
 Paton, N. I., e129
 Patrick, C. C., 36, 1456
 Patterson, T. F., 295
 Pavlov, R., e176
 Paya, C. V., 596, 1237
 Pearson, T. A., 1456
 Peck, K. R., 1463
 Pediatric AIDS Clinical Trials Group 230 Collaborators, 801
 Peermans, W. E., e9, 527
 Peipert, J., 476
 Peitsch, W. K., e145
 Peltola, H., 64, 715
 Pelton, S. I., 1155
 Pendle, S., 44
 Perencevich, E. N., 317
 Perera, J., 1463
 Perez, C., e105
 Pérez-Trallero, E., e158
 Perkins, B. A., 708
 Perlín, D., 1034
 Perlman, D. C., 623
 Perronne, C., 1207
 Peters, G., 1643
 Peters, W., 546
 Peterson, L. R., 605
 Petric, M., 1674
 Petrucca, A., e15
 Pettus, P. T., 140
 Pfaller, M. A., S114, S156
 Phair, J., 396
 Phan, H. M., 307, 534
 Phantumchinda, K., e117
 Phelan, M., 1215, 1448
 Phetsouvanh, R., 653
 Phillips, P., 845
 Phipatanakul, W., e13
 Phongmany, S., 653
 Phuong, C. X. T., 204
 Phuong, N. T. Q., 204
 Pickering, L. K., 331
 Piecuch, S., 130
 Piedra, P. A., 1423
 Pierce, K., 1651
 Pierre, C., 991
 Pietrobon, P., 170
 Pigray, C., 1024
 Pineda, J. A., 633
 Pinedo, A., 159
 Piñeiro, L., e158
 Pinner, R. W., 573
 Pitchenik, A. E., 323
 Pitlik, S., e176
 Pizov, G., 1502
 Platt, R., 140, 686
 Pleconaril Treatment Registry Group, 228
 Pliakatis, B. D., 708
 Plotkin, S. A., 1068
 Polish, L. B., 1331
 Polywka, S., 144
 Ponce, C. A., 855
 Pons, J.-L., 326
 Popara, M., 44
 Portegies, P., 1095
 Portsmouth, S., 469
 Poulakou, G., 1718
 Powderly, W. G., 124
 Pozio, E., 638
 Prabhakar, P., 890
 Pratlong, F., 302
 Press, N., 808
 Price, P., 325
 Prijanto, M., 1039
 Prince, T. L., e17
 Principi, N., 1281
 Prins, J. M., 1095
 Procop, G. W., 1589
 Puerzer, M., 979
 Puklin, J. E., 1661
 Pur, S. L., 694
 Pyörlä, K., 1141
 Quagliarello, V., 755
 Quaglio, G., e143
 Quang, V. M., e78
 Quinn, T. C., 655
 Raad, I., e94, 186, 539, 871, 1249
 Rabaud, C., 1494
 Raccurt, C. P., e154
 Raffalli, J. T., 862
 Raffi, F., 162, 963
 Raguin, G., 1207
 Rahaman, M., 884
 Ramanathan, J., 1381
 Ramaswamy, R., 1231
 Ramchatesingh, J. E., 1387
 Ramgopal, M., 662
 Ramon, J., 822
 Ramphal, R., S146, 381
 Ramsay, A., 653
 Ranger-Rogez, S., 197
 Raoult, D., 897, 1440
 Rastegar, D. A., 502
 Raveh, D., 559
- Ravnik, I., e31
 Razzouk, B. I., 1456
 Reagan-Cirincione, P., 220
 Rebuck, J. A., e83
 Reddy, B. T., e145
 Reed, G. W., 847
 Reed, K. D., 1434
 Reeves-Hoché, M. K., 170
 Regnery, H., 1784
 Régnier, B., 1133
 Reid, K. C., 1540
 Reilly, D. T., 419
 Reimer, L. G., 498
 Reingold, A., 708
 Reiter, C., 1112
 Reller, L. B., 331, 975
 Relman, D. A., 457
 Rennie, R., S146
 Residori, M., e143
 Rex, J. H., 518, 1191, 1713
 Richard, P., 162
 Richardson, S., 1554, 1674
 Richet, H., 162
 Riddell, D., 862
 Riederer, K. M., 1381
 Rietschel, P., 130
 Rigter, A., e97
 Rijkers, G. T., 1700
 Ritchie, D. J., 1373
 Riveau, G., e154
 Rivero, A., 159
 Roberson, P. K., 36
 Roberts, N., 150
 Roberts, S. A., 647
 Rodriguez, N., e158
 Roemer, E., e1
 Rogers, D., 708
 Röllinghoff, M., 302
 Rolston, K., e145, 539, 871
 Romero, G. A. S., 1304
 Rönnberg, P.-R., 1141
 Rosa, A., e154
 Rosado-Santos, H., 498
 Rose, G., 636
 Rosenberg, Z., 476
 Rosenstein, C., 352
 Rosenstein, N. E., 708
 Rosenthal, E., 1207
 Ross, L. L., 636
 Ross, M. J., e120
 Rotbart, H. A., 228
 Roth, D., 662
 Rothman, R. E., 655
 Rouslanova, I., 842
 Roussel-Delvallez, M., S81
 Ruben, F. L., 170
 Rubinger, D., 1502
 Rubinstein, E., 402, 728, 822
 Rudensky, B., 559
 Ruef, C., 581
 Rupoli, S., 1414
 Rupp, M. E., e83
 Rutala, W. A., 446, 1348
 Saba, R., 1658
 Sacchi, L., 638
 Sacchini, D., 638

- Sack, D., 396
 Sack, R. B., 331
 Sacks, L. V., 44
 Sader, H. S., S104, S156
 Saengwonloey, O., 955
 Sagar, B., 153
 Sagui, E., 991
 Sahgal, N. B., 826
 Saikku, P., 1141
 Sajjad, Z., 1366
 Sakamaki, H., 1325
 Sakashita, C., 1325
 Sakoulas, G., e120
 Salata, R. A., 1487
 Sale, G., 214
 Salminen, S., 1577
 Salzman, D., 1319
 Samore, M. H., 317, 1055
 Sampathkumar, P., 1237
 Samper, S., 159
 Samra, Z., e176
 Samson, I., 527
 Sanchez, H., e1
 Sánchez, M. A., 159
 Sánchez-Quijano, A., 633
 Sanders, C. C., S1
 Sanders, C. V., 1430
 Sanders, L. A. M., 1700
 Sandlund, J. T., 36
 Sandridge, A., 50
 Santana, V. M., 36
 Santolaya, M. E., 855
 Santos, J., 159
 Sanz, M., 1532
 Saravolatz, L. D., 1562
 Sarid, R., 1502
 Saulsbury, F. T., e137, 464
 Sax, P., 130, 140
 Scalari, P., 1414
 Scanvic, A., 1393
 Schaffner, A., 1233
 Schaffner, W., 23
 Schantz, P. M., e111
 Scheib, R., 492
 Schellenberg, R. R., 1685
 Schentag, J. J., S39
 Schioppa, O., 1100
 Schlech, W. F., III, 1519
 Schlemmer, B., 30
 Schlesinger, Y., 559
 Schmader, K., 1481
 Schmid, D., 838
 Schmidt, E. V., 1004
 Schmitz, F. J., S114
 Schönian, G., 302
 Schranz, J., 358
 Schroeder, J., 842
 Schuhmacher, H., 1494
 Schulman, G., 23
 Schuster, M. G., 391
 Schwartz, F., 1502
 Schwarz, T., 1643
 Schwebke, J. R., 325
 Seage, G. R., III, 783
 Sebti, A., 1034
 Segar, D. L., 686
 Segreti, J., 694
 Segura, J. C., 506
 Seiler, S. M., 1331
 Semba, R. D., 1496
 Senining, R. C., e100
 Sentinel Health Unit Surveillance System Pertussis Working Group, 1691
 SENTRY Participants Group, S114
 Senzileit, L. D., 1691
 Sepkowitz, K. A., 1034
 Sereti, I., 1738
 Shabtai, M., 822
 Shah, M. A., 647
 Shahzad, R., e100
 Shamoon, A., e87
 Sharara, A. I., 820
 Sharghi, N., e111
 Sharma, M. D., 153
 Sheagren, J. N., e131
 Shenep, J. L., 36, 1456
 Sherertz, R. J., 1249
 Shevitz, A. H., 1769
 Shibli, A. M., 1463
 Siegel, M., 972
 Simdon, J., 1623
 Simonart, J.-M., e9
 Simonart, T., e9
 Simpson, J. A., 204
 Singh, N., 742
 Singleton, T. P., 983
 Sirisantha, T., 955
 Siwi, S., 1235
 Sixbey, J. W., 36
 Skahan, K. J., 1215
 Slain, D., 321
 Slater, K., 979
 Slaven, E. M., 1430
 Slobod, K. S., 36
 Slutsker, L., 331, 573
 Smaczy, C., 1648
 Small, P. M., 1580
 Smayevsky, J., S114
 Smego, R. A., 289
 Smilack, J. D., 1448
 Smith, B., 1691
 Snoeck, R., e62
 Snyderman, D. R., 492
 Sobel, J., 518, 1191, 1602, 1661
 Sočan, M., e31
 Soeiro, R., 1108
 Soewignjo, S., 1039
 Solera, J., 506
 Solomon, T., 204
 Song, J.-H., 1463
 Soto, N. E., e100
 Sovrć, M., 838
 Spaendonck, M. A. E. C., 2
 Spanjaard, L., 1700
 Speelman, P., 650
 Spellberg, B., 76
 Spika, J. S., 1691
 Stadtmauer, E., 391
 Stahl-Avicilli, A., e100
 Stambaugh, J. J., 323, 515
 Stamm, W. E., 255
 Stanley, S., 1373
 Stanley, T., 130
 Starlin, R., 1373
 Stass, H., S47
 Steffen, R., 1706
 Steinbach, G., 832
 Steiner, T. S., 331
 Steinhoff, M., 1039
 Stellini, M. A., e90
 Stén, M., 1141
 Stephens, J. L., e107
 Stevens, D. L., e24
 Stoekli, T. C., 836
 Stone, D., 492
 Storch, G. A., 1628
 Stout, J. E., 1562
 Stratov, I., 236
 Strausbaugh, L. J., 270
 Stroobants, S., 191
 Stroud, T. P., 1319
 Stutman, P., 307
 Su, L., 686
 Suankratay, C., e117
 Suh, K. N., 483
 Sultan, Z., 884
 Sundar, K. M., 498
 Sutanto, A., 1039
 Svaborg, C., 1523
 Svensson, M., 1523
 Svetlansky, I., 1110, 1656
 Szilak, I., 1108
 Tachawiboonsak, W., e117
 Tack, K. J., 381
 Taddio, R., 352
 Taha, T. E., 1496
 Talan, D. A., S64, 573
 Talbot, R., 708
 Tam, D. T. H., 243
 Tam, W.-H., 1376
 Tamburini, A., 638
 Tan, J. S., 1562
 Tang, Y.-W., 23
 Tanikawa, S., 1325
 Tankovic, J., e92
 Tappero, J. W., 373
 Tarkiainen, A., 1141
 Tarr, P., 331
 Tarrand, J., 539
 Tashima, K. T., 970
 Tateishi, H., e22
 Tauke, R. V., 331
 Taylor, G., 167
 Taylor, S. L., 647
 Taylor-Robinson, D., 995
 Teague, B. A., e111
 Tee, N. W.-S., e129
 Tenorio, A. R., 826
 Tenover, F. C., 605
 Teo, T.-P., e129
 Territo, M. C., 381
 Teutsch, S. M., 358
 Theodore, S., 1155
 Thielman, N. M., 331
 Thien, V. V. S., 1685
 Thiéry, G., e92
 Thimmappa, B., 515
 Thomas, B., 995
 Thomas, E., 300
 Thomas, K., 1463
 Thomason, J. L., 103
 Thompson, S., 1706
 Thompson, S. J., 1456
 Thomson, M. M., 1732
 Thomson, R. B., Jr., 605
 Thomson-Carter, F., e97
 Thonell, L., 44
 Thorpe, C. M., 1517
 Thursky, K., e65
 Thuy, T. T. N., 243
 Ticona, E., 808
 Tiengrim, S., 1463
 Tilden, R. L., 862
 Tillotson, G., S22, S51, S72, 1112
 Tillotson, G. S., 1189
 Timpone, J., 972
 Tirelli, U., 1100
 Tompkins, L. S., 605
 Tønning, B., 987
 Torresi, J., e65
 Torrey, E. F., 842
 Torronteras, R., 17
 Totzuka, K., 1399, 1408
 Towne, L., 1178
 Traccardi, I., 197
 Trenholme, G. M., 826
 Trupl, J., 1656
 Truskovsky, A. M., e36
 Tsang, K. W. T., 701
 Tse, W. S., 701
 Tselis, A. C., e90
 Tsukahara, M., e22
 Tsuneoka, H., e22
 Tuazon, C. U., 1313
 Tukiainen, H., 1141
 Tuomanen, E., 552
 Turk, B. K., 140
 Turnidge, J., S146, S156
 Uchida, M., e22
 Uehara, Y., 1399, 1408
 Ulloa, A. V., 855
 Uzun, Ö., e59, 1713
 Vachon, F., 1133
 Valassina, M., 1241
 Valdez, H., 1487
 Van, P. H., 1463
 van den Hof, S., 2
 Vander Heide, R. S., 313
 van der Horst, C., 124
 van der Kraak, P. H., 2
 Vandermouse, M., 1434
 van der Meir, J. T. M., e81
 van der Poll, T., e81, 650
 van Deventer, S. J. H., 650
 van Dissel, J. T., 323
 Van Gilder, T., 331
 Van My, N., 204
 Vanoli, C., 581
 Van Thien, C., 204
 Van Valckenborgh, I., e62
 Van Vooren, J.-P., e9
 Van Wijngaerden, E., 527

- Vargas, S. L., 855
 Vaudry, W. L., 1637
 Veenstra, J., 650
 Venard, V., 1290
 Venot, C., 197
 Vento, S., e143
 Ventura, W., 50
 Verbon, A., 650
 Verenkar, M. P., 1706
 Verhoeft, J., S104, S156
 Verleysen, A., e9
 Verraes, S., e9
 Vexiau, P., 30
 Veyssier, P., 1207
 Vignon, P., 197
 Villasenor-Sierra, A., e24
 Vinitius de Farias Guerra, M.,
 1304
 Viral Activation Transfusion
 Study, 116
 Visca, P., e15
 Viscoli, C., 1532
 Vivar, R., S30
 Vivarelli, A., 1241
 Vizzi, E., 1126
 von Eiff, C., 1643
 Vu, C. K.-F., e129
 Vugia, D., 708
 Vuori-Holopainen, E., 715
 Wagenaar, J. A., e97
 Walker, B. D., 1756
 Wallace, R. J., Jr., 1547, 1648
 Wallach, F., 116, 667
 Walls, J. I., 862
 Walmsley, S., 1554
 Walsh, T. J., 518
 Walter, E. A., e140, 1639
 Wang, S., 153
 Wang, V. J., 1004
 Wang, Y. C., 373
 Wanke, C. A., 1710
 Wara, D. W., 801
 Ward, J. W., 794
 Ward, K. N., 413
 Ware, A. J., e122
 Warnock, D. W., 1448
 Warren, D. K., 1331
 Warsa, U. C., 1463
 Watson, A., 660
 Watters, D., 1623
 Weber, D. J., 446, 1348
 Webster, A. D., 228
 Wegener, S., S22
 Weinberg, A., 815
 Weingarten, M. S., 949
 Weinstein, M. C., 783
 Weinstein, R. A., 826
 Weiss, H., 325
 Weissman, S. B., 1487
 Wellens, W., e62
 Weller, P. E., 317
 Wenzel, R. P., 1538
 Werner, S. B., 708
 West, D. C., 1659
 Wheat, L. J., 1215
 Whimbey, E., e145, 539, 871
 White, A. C., Jr., 153, 1516
 White, N. J., 204, 243, 653
 Whittington, W. L. H., 1313
 Wi, T., 1313
 Widjaya, A., 1039
 Wilde, H., e117
 Wilfert, C. M., 605
 Williams, P., 1615
 Wills, B., 204
 Wilson, M., 660
 Wilson, M. E., 1378, 1589
 Wilson, P. W. E., 130
 Winkelstein, J. A., e13
 Winokur, P. L., S94
 Winston, D. J., 381
 Witz, F., 1290
 Wocker, E. L., e1
 Wolf, D. G., 1502
 Wolff, M., 1133
 Wolfhagen, M. J. H. M., 311
 Wolfs, T. F. W., e97
 Won, K. Y., 1010
 Wong, M., 1034
 Wong, S. J., 1784
 Wong, S. S., e39
 Wood, D., 307
 Woodhouse, L., 170
- Woodhouse, S., 1795
 Woolley, I. J., 1487
 Wormser, G. P., 862
 Wu, J.-L., 1463
 Wunderink, R. G., 402
 Wuthiekanun, V., 653
 Wywiol, A., 144
 Yang, Y., 824, 1463
 Yasmin, L., 884
 Ye, Y., 1554
 Yee, T. T., 1463
 Yeo, W., 1376
 Yiannoutsos, C. T., 1517
 Yinnon, A. M., 559
 Yip, M. C., 1639
 Yolkem, R. H., 842
 Yoshioka, M., e57
 Yu, D. T., 686
 Yuen, K.-y., 846
 Yukna, M., 352
 Zakotnik, B., e31
 Zbinden, R., 581
 Zeller, B., 1784
 Zenilman, J. M., 655
 Zervos, M., 1657
 Zhang, H., 783
 Zheng, H., 1325
 Zhong, S., 1376
 Zinkernagel, A. S., 1233
 Zwaan, F., e87

SUBJECT INDEX

- Abiotrophia* infections, bacteremia, drug-resistant, e140
Abortion, spontaneous, in brucellosis, 1172
Abscess
 abdominal, due to *Brucella*, 1024
 brain
 due to *Aspergillus*
 in bone marrow transplantation, 1319
 treatment, e137
 due to *Streptococcus intermedius*, treatment, e131
breast, due to *Staphylococcus aureus*, toxic shock syndrome in, 1470
due to *Edwardsiella tarda*, 1430
due to *Fusarium*, in heart-liver transplantation, 1237
liver, due to *Fusobacterium nucleatum* [letter], 326
due to *Salmonella*, 263
spinal epidural, in pediatric patients, 9
due to *Streptococcus intermedius*, hepatopulmonary syndrome in, treatment, e131
due to *Streptococcus milleri* group, 1511
tubo-ovarian, Centers for Disease Control and Prevention guidelines, 103
visceral
 due to *Brucella suis*, e129
 in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
Acinetobacter infections
 catheter-related, guidelines, 1249
 resistance in, global, S104, S156
Acquired immunodeficiency syndrome (*see* Human immunodeficiency virus infection)
Acrodermatitis continua of Hallopeau, digital, 431, 505
Actinomycetes infections, pathology, 1589
Acylovir
 for cytomegalovirus infections, prophylactic, 596
 for eczema herpeticum, 1480, 1500
 for herpes simplex virus, in HIV infection, 611
 for herpes zoster, 1481
 for HIV opportunistic infections, lymphoma and [letter], 989
 resistance to, herpes simplex virus, 611
Adenovirus infections
 in bone marrow transplantation, 871
 hemorrhagic cystitis in, 1325
 pathology, 1589
 respiratory, in Korean children, 1423
 in stem cell transplantation, 1290
 type 7d2, outbreaks, 694
Aeromonas infections, diarrhea, practice guidelines, 331
Aerosol treatment, with aminoglycosides, for tuberculosis, 44
AIDS (*see* Human immunodeficiency virus infection)
Albendazole
 for gnathostomiasis, e154
 for hydatidosis, thigh muscle, e65
 resistance to, *Giardia lamblia*, 1792
Alcohol, in hand cleansing gel, artificial fingernail colonization and, 367
Allergic reactions
 to meningococcal vaccines, 1273
 to penicillins, skin testing for, 317, 1685
Alternariasis, in diabetes mellitus, 1178
Amantadine, for hepatitis C, 830
Amblyomma species, review, 897
Amebiasis, practice guidelines, 331
American Hospital Association, on Medicare overcharges for pneumonia, Current News, May 15
Amikacin
for meningitis, tuberculous, 643
resistance to, 1162
Acinetobacter, S104
extended-spectrum β -lactamase-producing organisms, S94
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
Aminoglycosides
for *Staphylococcus aureus* infections, vancomycin-resistant, 108
for tuberculosis, refractory, 44
Amitriptyline, for herpes zoster, 1481
Amoxicillin
 resistance to, *Haemophilus influenzae*, S81
 for syphilis, in HIV infection, 611
Amphotericin B
 for alternariasis, in diabetes mellitus, 1178
 for aspergillosis, 358
 in bone marrow transplantation, e94
 for *Candida lusitaniae* infections, 186
 for candidiasis, in neonates, 1018
 for endocarditis, 50
 for fever, in neutropenia [letter and reply], 320, 518
 for *Fusarium* infections, in heart-liver transplantation, 1237
 for intravascular catheter-related infections, 1249
 kidney failure due to, economic impact of, 686
 lipid formulations, liver injury due to, e87
 nephrotoxicity, 686, 990 [letter]
 for osteomyelitis, due to *Candida*, 527
 for urinary tract infections, due to *Candida*, 1602
Ampicillin
 for intravascular catheter-related infections, 1249
 resistance to, *Enterococcus*, S133
Amplicor test, for *Mycobacterium tuberculosis*, in pediatric patients, 17
Anaerobic organisms, in vaginal flora, e69
Anatomic pathologist, in infection diagnosis, 1589
Andes hantavirus infections, nosocomial, prevention, 446
Anemia
 in babesiosis, 1117
 in malaria, 1133
 in parvovirus B19 infections, 167
 in HIV infection, e122, 1361
Angiography, coronary, *Corynebacterium jeikeium* endocarditis after, e120
Animal(s), prion diseases in, 1726
Animal studies
 moxifloxacin activity, S16, S22
 T lymphocyte type 1/type 2 immunity, 76
Ankylosing spondylitis, pulmonary fibrosis in, 1062, 1103
Anorectal infections, in HIV infection, 611
Anthrax, nosocomial, prevention, 446
Anthropometry, in HIV infection, 130
Antibiotics (*see also* specific antibiotics)
 book reviews, 1245
 lock therapy with, 1249
 prophylactic (*see* Prophylaxis)
 resistance to (*see* Drug resistance)
 selection, new β -lactamases and, 1085
 susceptibility to (*see* Susceptibility testing)
 toxicity, S72
 use patterns, resistance development and, 1044, 1189
Antibody(ies)
 Haemophilus influenzae, after vaccination, 2
 HIV, 1756
pneumolysin, in *Streptococcus pneumoniae* infection diagnosis, 534
streptococci, group A, e24
T lymphocyte type 1/type 2 immunity and, 76
Toxoplasma gondii, in schizophrenia, 842
Antidepressants, for herpes zoster, 1481
Antigen(s), dose of, in T lymphocyte type 1/type 2 immunity, 76

- Antigen-presenting cells, T lymphocyte type 1/type 2 immunity and, 76
 Antipyretic drugs, for malaria, in pediatric patients, 838
 Aorta, fungal vegetations in, 50
 Area under the inhibitor concentration curve, practical use, S39
 Argasidae (soft ticks), review, 897
 Argentine hemorrhagic fever, nosocomial, prevention, 446
 Arthralgia
 in babesiosis, 1117
 due to quinupristin-dalfopristin, e83
 in Whipple's disease, 457
 Arthritis
 rheumatoid, *Bartonella* infections in, e22
 septic
 due to *Burkholderia pseudomallei*, 653
 due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
 Arthropathy
 fluoroquinolone-induced, S72
 in parvovirus B19 infections, 167
 Arthroplasty, hip, infections, treatment, 419
 Arthropod infections, pathology, 1589
 Aseptic meningitis
 in enterovirus 71 infections, 236
 after neurological surgery, vs. bacterial meningitis, 179
 Asian Network for Surveillance of Resistant Pathogens, pneumococci, 1463
Aspergillus flavus infections, spinal epidural abscess, in pediatric patients, 9
Aspergillus infections
 in bone marrow transplantation, treatment, e94
 brain, treatment, e137
 endocarditis, literature review, 50
 invasive
 in bone marrow transplantation, 1319
 mortality in, 358
 pathology, 1589
 Aspiration, lung fluid, for pneumonia diagnosis, in pediatric patients, 715
 Asthma, risk factors, *Toxocara*, e111
 Ataxia, cerebellar, in enterovirus 71 infections, 236
 Atovaquone, for babesiosis, 1117
 AUIC (see Area under the inhibitory concentration curve)
 Avascular necrosis, bone, in HIV infection, 1221
 Azithromycin
 for babesiosis, 1117
 for brucellosis, 506
 for diarrhea, 331
 for legionellosis, failure, 1562
 for *Mycobacterium avium* complex infections, 1547
 prophylactic, in HIV infection, 1615
 resistance to, *Streptococcus pneumoniae*, S81
 for streptococcal pharyngitis, 1798
 Aztreonam
 for intravascular catheter-related infections, 1249
 for pneumonia, nosocomial, 402
 resistance to
 Escherichia coli, S94
 Klebsiella pneumoniae, S94
 Proteus mirabilis, S94
 Pseudomonas aeruginosa, S146
 Babesiosis
 in nonspecific fever study, 1434
 review, 897
 severe, complications, 1117
Bacillus cereus infections
 bacteremia, venous port-related, 1776
 in immunodeficiency, in pediatric patients, 1456
 Bacteremia
 due to *Abiotrophia*, drug-resistant, e140
 due to *Bacillus cereus*, in immunodeficiency, in pediatric patients, 1456
 blood culture for, usefulness, 1651
 after bone marrow or stem cell transplantation, 391, 546
 breakthrough, in neutropenia, antifungal prophylaxis and, 1532, 1538
 due to *Burkholderia pseudomallei*, 653
 catheter-related
 in cancer, 1776
 guidelines, 1249
 in HIV infection, 1776
 due to *Clostridium tertium*, 975
 due to *Edwardsiella tarda*, 1430
 due to *Enterococcus*
 mortality in, 587
 resistance in, S133
 vancomycin resistance and, 1110, 1112 [letter and reply], 1381
 due to *Enterococcus casseliflavus/flavescens*, 1540
 due to *Enterococcus gallinarum*, 1540
 due to *Escherichia coli*, virulence factors in, 1523
 due to gram-negative bacteria, in cancer, prediction, 832
 due to *Haemophilus influenzae*, resistance in, S81
 in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
 due to *Moraxella catarrhalis*, resistance in, S81
 due to *Neisseria meningitidis*
 epidemiology, 1004
 protein C replacement in, 1338
 occult, epidemiology, 559
 due to *Salmonella*, 263
 due to *Staphylococcus*, e53
 resistance in, S114
 due to *Staphylococcus aureus*, e53
 prosthetic joint infections in, 647
 due to *Stenotrophomonas maltophilia*, susceptibility testing [letter], 1656
 due to *Streptococcus pneumoniae*
 pneumolysin antibody detection in, 534
 resistance in, S81
 serogroups, in pediatric patients, 1155
 due to *Vibrio cholerae* non-serogroup O:1, e117
Bacteroides infections, resistance in, trimethoprim-sulfamethoxazole, 1608
Bartonella infections
 in juvenile rheumatoid arthritis, e22
 pathology, 1589
 Basidiobolomycosis, gastrointestinal, epidemiology, Arizona, 1448
 Basil, *Cyclospora* in, 1010
 BAY y 3118 (quinolone), activity, S16
 Bee stings, fatal infections after, e36
 Benzathine penicillin G, for syphilis, in HIV infection, 611
 Bichloroacetic acid, for human papillomavirus infections, 611
Bifidobacterium, as probiotic, 1567, 1577
 Bile ducts, *Fasciola hepatica* infection, 727, 820
 Binax NOW assay, for *Streptococcus pneumoniae* infections, in pediatric patients, 824
 Biopsy, in infection diagnosis, 1589
 Bioterrorism
 clinical microbiology laboratory services and, 604, 605
 preparation for
 TOPOFF exercise, 436
 West Nile viral encephalitis outbreak observations, 277
 threat of, 675
 zoonotic diseases in, 446
 Bites

- spider, vs. infections, 595, 636
- tick (*see also* Ticks, diseases transmitted by; specific diseases) review, 897
- Bithionol, for *Fasciola hepatica* infections, 727, 820
- BK virus infections, in bone marrow transplantation, 1325
- Blackwater fever, in malaria, 1133
- Bladder, hemorrhagic cystitis, in bone marrow transplantation, due to adenovirus, 1325
- Blastomycosis pathology, 1589
public health response to, in Colorado, e151
- Bleeding, gastrointestinal, in HIV infection, 1487
- Blood counts, during human granulocytic ehrlichiosis, 862
- Blood culture for bacteremia occult, 559 usefulness, 1651
for pneumonia, vs. lung tap, 715
- Blood transplantation (*see* Stem cell transplantation)
- B lymphocytes, T lymphocyte type 1/type 2 immunity and, 76
- Bolivian hemorrhagic fever, nosocomial, prevention, 446
- Bone lesions (*see also* Osteomyelitis)
avascular necrosis, in HIV infection, 1221
spinal, in pediatric patients, 9
due to *Treponema pallidum*, in HIV infection, 667
- Bone marrow transplantation adenovirus infections in, 871, 1325
aspergillosis in, e94
Candida lusitaniae infections in, 186
hemorrhagic cystitis in, 1325
infectious complications, after 1 year, 391
invasive fungal infections in, 1319
Scedosporium prolificans infections in, e158
- Book reviews
The Antimicrobial Drugs, 521
Diagnostic and Therapeutic Antibodies, 670
Drug Interactions in Infectious Diseases, 1245
Handbook of Antibiotics, 1245
Management of Antimicrobials in Infectious Diseases: The Impact of Antibiotic Resistance, 671
New Concepts in the Immunopathogenesis of CNS Infections, 1244
Progress in Vaccinology, 522
- Bordetella pertussis* infections in adults and adolescents, 1691, 1698
epidemiology, in elderly persons [letter], 847
- Borreliosis (*see* Lyme disease)
- Boutonneuse fever, review, 897
- Bovine spongiform encephalopathy, clinical implications, 1726
- Brain abscess
due to *Aspergillus*
in bone marrow transplantation, 1319
treatment, e137
due to *Streptococcus intermedius*, treatment, e131
infarction, in *Mycoplasma pneumoniae* infections, e31
infections (*see also* Encephalitis; Meningitis)
book reviews, 1244
surgery on, chemical meningitis after, vs. bacterial meningitis, 179
tumorlike mass in, due to *Schistosoma mansoni*, 1347, 1371
- Breast abscess, due to *Staphylococcus aureus*, toxic shock syndrome in, 1470
- Breast cancer, bone marrow or stem cell transplantation in, infectious complications, 391, 546
- Breast-feeding, *Helicobacter pylori* infection epidemiology and, 1387
- Bronchiolitis, due to adenovirus, in Korean children, 1423
- Bronchitis
- in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
treatment, moxifloxacin, S51, S64
- Bronchoalveolar lavage fluid, in tuberculosis diagnosis, 17
- Brown recluse spider bites, vs. infections, 595, 636
- Brucella suis* infections, abscess, e129
- Brucellosis chronic hepatosplenic suppurative, 1024
endocarditis in, skin lesions with, 63, 149
in pregnancy, 1172
treatment, 506
- BufferGel vaginal microbicide, safety, 476
- Burkholderia cepacia* infections, catheter-related, guidelines, 1249
- Burkholderia pseudomallei* infections in cystic fibrosis, e15
epidemiology, Laos, 653
- Bursitis, septic, in pediatric patients, e102
- B virus infections, nosocomial, prevention, 446
- Campylobacter fetus* infections, in HIV infection, 295
- Campylobacter* infections, diarrhea epidemiology, 573
practice guidelines, 331
- Campylobacter jejuni* infections epidemiology, 1201
resistance in, 1201
sulfonamides, 1608
sepsis, in pediatric patients, e97
- Cancer
Aspergillus infections in, mortality in, 358
bacteremia in, due to venous access port, 1776
breast, bone marrow or stem cell transplantation in, infectious complications, 391, 546
Candida dubliniensis infections in, 1034
Candida lusitaniae infections in, 186
candidemia in, outcome, 1713
Cryptococcus neoformans infections in, e145
fever in, imaging studies, 191
due to human papillomavirus, in HIV infection, 611
infectious causes, 675
Legionella infections in, treatment failure, 1562
liver, in hepatitis C, in HIV infection, 1207
neutropenia in
bacteremia breakthrough, antifungal prophylaxis and, 1532, 1538
gram-negative bacteremia prediction in, 832
treatment, in children, 36
- Salmonella* infections in, 263
- Scedosporium prolificans* infections in, e158
- Stenotrophomonas maltophilia* infections in, susceptibility testing [letter], 1656
- Candida*, resistance to, 1554
- Candida albicans*, in vaginal flora, e69
- Candida albicans* infections bacteremia, venous port-related, 1776
pathology, 1589
- Candida dubliniensis* infections, in cancer, 1034
- Candida* infections (candidiasis)
in bone marrow or stem cell transplantation, 546
catheter-related, guidelines, 1249
endocarditis, literature review, 50
in HIV infection, oropharyngeal, 1554
osteomyelitis, vertebral, 527
prophylaxis, in intensive care unit, 1191
T lymphocyte type 1/type 2 immunity in, 76
vaginitis, treatment with probiotics, 1567
- Candida lusitaniae* infections, in cancer, 186

- Candidemia
 in cancer, outcome, 1713
 in neonates, systemic involvement, 1018
 nosocomial, costs [letter], 1100
 vertebral osteomyelitis in, 527
- Candiduria, nosocomial, review, 1602
- Carbapenems
 for intravascular catheter-related infections, 1249
 resistance to, new β -lactamases and, 1085
- Cardiac arrhythmias, fluoroquinolone-induced, S72
- Cardiomyopathy
 dilated, due to *Coxiella burnetii*, 1440
 in HIV infection, highly active antiretroviral therapy effects on, in pediatric patients, 464
- Cardiovascular disease, in HIV infection, 130
- Carditis, due to *Coxiella burnetii*, 1440
- Carriage (see Colonization)
- Case-control studies, drug resistance risk factors, methodological principles, 1055
- Case reports, editorial policy on, 1
- Catecholamines, in T lymphocyte type 1/type 2 immunity, 76
- Catheter-related infections
 urinary, due to *Candida*, 1602
 vascular
 after bone marrow or stem cell transplantation, 391, 546
 in cancer, 1776
 guidelines, 1249
 in HIV infection, 1776
- Cefaclor, resistance to, *Streptococcus pneumoniae*, S81
- Cefepime
 for intravascular catheter-related infections, 1249
 resistance to
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
- Cefixime
 for febrile neutropenia, in pediatric patients, 36
 for gonorrhea, 1313
 in HIV infection, 611
- Cefmenoxine, area under inhibitory concentration curve values, S39
- Cefotaxime
 resistance to, *Streptococcus pneumoniae*, 1463
 for *Vibrio cholerae* non-serogroup O:1 infections, e111
- Cefprozil, resistance to, *Streptococcus pneumoniae*, S81
- Ceftazidime
 for melioidosis, in cystic fibrosis, e15
 resistance to
 Acinetobacter, S104
 Escherichia coli, S94
 Klebsiella pneumoniae, S94
 Proteus mirabilis, S94
 Pseudomonas aeruginosa, S146
 Stenotrophomonas maltophilia, S104
- Ceftriaxone
 for diarrhea, 331
 for gonorrhea, in HIV infection, 611
 resistance to
 Escherichia coli, S94
 Klebsiella pneumoniae, S94
 Proteus mirabilis, S94
 for syphilis, in HIV infection, 611
- Cefuroxime, resistance to, *Streptococcus pneumoniae*, S81, 1463
- Cellular immune response
 in cellulitis, e17
 T lymphocytes in, type 1/type 2 immunity, 76
- Cellulitis
 after bone marrow or stem cell transplantation, 391, 546
- cellular immunity in, e17
 due to β -hemolytic streptococci, laboratory tests for, e9
 due to *Vibrio cholerae* non-serogroup O:1, e117
- Cell wall, fluoroquinolone effects on, S9
- Centers for Disease Control and Prevention guidelines, pelvic inflammatory disease, 103
- Central nervous system (see Brain; Spinal cord)
- Cephalosporinases, new, antibiotic therapy selection and, 1085
- Cephalosporins (see also specific drugs)
 for intravascular catheter-related infections, 1249
 resistance to
 new β -lactamases and, 1085
 Salmonella, 263
 for Whipple's disease, 457
- Cerebellar ataxia, in enterovirus 71 infections, 236
- Cerebritis, due to *Vibrio cholerae* non-serogroup O:1, e117
- Cerebrospinal fluid examination
 in chemical meningitis, 179
 in *Mycoplasma pneumoniae* encephalitis, 1674
 in syphilis, 611, 1661
 in toxoplasmosis, in stem cell transplantation, e1
- HIV in, after primary infection treatment, 1095
- Cervicitis, in HIV infection, screening for, 611
- Cervix, TT virus colonization, in pregnancy, 1376
- Cesarean delivery, toxic shock syndrome after, 1470
- CHAT poliomyelitis vaccine, HIV transmission hypothesis, 1068
- Chemical meningitis (see Aseptic meningitis)
- Chemokines and chemokine receptors, in HIV infection, in tuberculosis, 650
- Chemotherapy, *Bacillus cereus* infections after, in pediatric patients, 1456
- Chlamydia pneumoniae* infections pneumonia
 in Finland, 1141
 in pediatric patients, 1281
 resistance in, trimethoprim-sulfamethoxazole, 1608
- Chlamydia trachomatis* infections diagnosis, 103
 in HIV infection, 611, 808
- pelvic inflammatory disease, Centers for Disease Control and Prevention guidelines, 103
 resistance in, trimethoprim-sulfamethoxazole, 1608
 urethritis, 995
- Chloramphenicol
 for melioidosis, in cystic fibrosis, e15
 resistance to
 Enterococcus, S133
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 Streptococcus pneumoniae, 1039
- Cholera, practice guidelines, 331
- Chorioretinitis
 due to *Candida*, in neonates, 1018
 due to *Treponema pallidum*, 1661
- Chromobacterium violaceum* sepsis, in pediatric patients, e107
- Chronic fatigue syndrome
 information resources for, 938
 treatment with antiviral agents [letter], 1657
- Chronic granulomatous disease, brain abscess in, due to *Aspergillus*, e137
- Chronic obstructive pulmonary disease, *Streptococcus pneumoniae* infections in, levofloxacin-resistant, 701
- Cidofovir
 for adenovirus infections, in stem cell transplantation, 1290
 for progressive multifocal leukoencephalopathy, failure, 150
 for respiratory papillomatosis, e62
- Ciprofloxacin

- area under inhibitory concentration curve values, S39
 for *Chromobacterium violaceum* sepsis, e107
 for diarrhea, 331
 excretion of, 822
 for gonorrhea
 failure, 884
 in HIV infection, 611
 for histoplasmosis, in HIV infection, 483
 mechanisms of action, S9
 resistance to, S1
 Acinetobacter, S104
 Enterococcus, S133
 extended-spectrum β -lactamase-producing organisms, S94
 Neisseria gonorrhoeae, 1313
 Pseudomonas aeruginosa, S146
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 Stenotrophomonas maltophilia, S104
 toxicity, S72
 for *Vibrio cholerae* non-serogroup O:1 infections, e117
 Cirrhosis, in hepatitis C
 cryptococcosis with, myositis in, 1104
 in HIV infection, 1207
 Clarithromycin
 for *Mycobacterium avium* complex infections, prophylactic, in HIV infection, 1615
 resistance to, *Streptococcus pneumoniae*, S81
 for streptococcal pharyngitis, 1798
 Clinafloxacin
 for febrile neutropenia, 381
 pharmacodynamics, S39
 resistance to, S1
 Clindamycin
 for babesiosis, 1117
 resistance to
 Moraxella catarrhalis, S81
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 Streptococcus pneumoniae, S81
 for toxoplasmosis, e1
 Clofazimine, for leprosy, 930
Clostridium difficile infections
 colitis, after bone marrow or stem cell transplantation, 391
 diarrhea, practice guidelines, 331
 treatment, probiotics in, 1567
Clostridium infections, resistance in, trimethoprim-sulfamethoxazole, 1608
Clostridium tertium infections, bacteremia, 975
 Clotrimazole, prophylactic, in intensive care unit, 1191
 Coagulopathy, due to *Neisseria meningitidis*, protein C replacement in, 1338
 Coccidioidomycosis
 pathology, 1589
 risk factors for, 708
 Cognitive dysfunction, in *Mycoplasma pneumoniae* infections, e31
 Colitis, due to *Clostridium difficile*, after bone marrow or stem cell transplantation, 391
 Colonization
 artificial fingernails
 Candida, 352
 hand cleansing methods and, 367
 Candida
 artificial nails, 352
 vs. infection, 1602
 enterococci, vancomycin-resistant
 in hemodialysis, 23
 prevention, 826
 gram-negative organisms, in neonatal intensive care unit, 220
Mycobacterium, nontuberculous, in cystic fibrosis, 1298
Mycobacterium abscessus, in cystic fibrosis, 1648
 pneumococci, antibiotic-resistant, in Asian children, 1463
Scedosporium prolificans, e158
Staphylococcus aureus, methicillin-resistant
 after hospital discharge, 1393
 viridans streptococci effects on, in newborns, 1399, 1408
Streptococcus pneumoniae
 levofloxacin-resistant, 701
 in pediatric patients, Indonesia, 1039
 TT virus, in pregnancy, 1376
 vaginal, normal, e69
 Colony-stimulating factors, for HIV infection, 766
 Compression therapy, for chronic venous disease, 949
 Condylomata acuminata, due to human papillomavirus, in HIV infection, 611
 Confusion, due to *Toxoplasma gondii*, in stem cell transplantation, e1
 Congenital infections, due to *Candida*, 1579, 1637
 Conjunctivitis, in HIV infection, 1628
 Coronary angiography, *Corynebacterium jeikeium* endocarditis after, e120
 Corticosteroids
 for cancer, candidemia due to, outcome, 1713
 for herpes zoster, 1481
 for HIV infection, 1738
 spinal epidural lipomatosis due to, e90
 for panhypopituitarism, infections related to, 153
 Salmonella infections related to, 263
 in T lymphocyte type 1/type 2 immunity, 76
Corynebacterium infections, catheter-related, guidelines, 1249
Corynebacterium jeikeium infections, endocarditis, after coronary angiography, e120
 Costs (see Economic issues)
 Co-trimoxazole (see Trimethoprim-sulfamethoxazole)
 Cough, persistent, in pertussis, 1691, 1698
Coxiella burnetii infections
 myocarditis, 1440
 nosocomial, prevention, 446
 review, 897
 Creutzfeldt-Jacob disease
 prevention, disinfection and sterilization for, 1348
 variant, clinical implications, 1726
 Crimean-Congo hemorrhagic fever, nosocomial, prevention, 446
 Critical illness, human herpesvirus type 6 reactivation in, 197
 Crohn's disease, *Clostridium tertium* bacteremia in, 975
 Croup, due to adenovirus, in Korean children, 1423
Cryptococcus neoformans infections
 in cancer, e145
 in hepatitis C, myositis in, 1104
 in HIV infection, antigen detection in, false-negative results in, 836
 myelitis, 1235
 pathology, 1589
Cryptosporidiosis
 practice guidelines, 331
 treatment with paromomycin [letter and reply], 1516, 1517
 Culture
 blood
 for bacteremia
 occult, 559
 usefulness, 1651
 for pneumonia, vs. lung tap, 715
 intravascular catheter-related infections, 1249
Mycobacterium tuberculosis, in pediatric patients, 17
 stool, in diarrhea, 331
 Cushing's syndrome, due to corticosteroids, spinal epidural lipomatosis in, e90
 Cyclosporiasis, practice guidelines, 331

Cyclosporine, for HIV infection, 1738
Cystic fibrosis
 Burkholderia pseudomallei infections in, e15
 Mycobacterium abscessus colonization in, 1648
 nontuberculous mycobacterial infections in, 1298
Cystitis
 due to adenovirus, in bone marrow transplantation, 871, 1325
 due to *Candida*, 1602
Cytokines
 for HIV infection, 766, 1738, 1756
 T lymphocyte type 1/type 2 immunity and, 76
Cytology, in infection diagnosis, 1589
Cytomegalovirus infections
 chronic fatigue syndrome in [letter], 1657
 diagnosis, 596
 disseminated, without HIV infection or transplantation, 313
 in HIV infection
 antibiotic prophylaxis for, 116
 preemptive treatment vs. prophylaxis, 783
 retinitis, 815
 pathology, 1589
 pneumonia, in leukemia, 539
 recurrent, in multiple organ failure syndrome, 197
 retinitis
 in HIV infection, Current News, May 1
 after stem cell transplantation, 214
thrombosis in, 983
in transplantation
 preemptive treatment vs. prophylaxis, 742
 prevention, 596

Dapsone
 for leprosy, 930
 for *Mycobacterium avium* complex infections, prophylactic, in HIV infection, 1615
Darier's disease, *Staphylococcus aureus* intracellular persistence in, 1643
Databases, for travel medicine, 757
Debridement, infected hip arthroplasty, 419
Decision-making, in simulated bioterrorist attack, 436
Dengue hemorrhagic fever
 microvascular leakage in, noninvasive measurement, 243
 reemergence, 675
 treatment, 204
Dermacentor species, review, 897
Desipramine, for herpes zoster, 1481
Diabetes mellitus
 alternariosis in, 1178
 coccidioidomycosis risk in, 708
 ketoacidosis in, infection as trigger, 30
 Salmonella infections in, 263
Diarrhea
 bloody, epidemiology, 573
 due to *Campylobacter jejuni*, epidemiology, 1201
 due to *Clostridium difficile*, treatment, probiotics in, 1567
 due to enteropathogenic *Escherichia coli*, in travelers, 1706, 1710
 infectious, practice guidelines for, 331
 due to rotavirus, severity, vs. viral strain, 1126
 due to *Tropheryma whipplei*, 457
Didanosine, for HIV infection
 ototoxicity, 1623
 resistance to, monitoring, 774
Dihydrofolate, inhibition, trimethoprim-sulfamethoxazole in, 1608
Disinfection, Creutzfeldt-Jacob disease prevention, 1348
Diskitis, due to *Candida*, after spinal surgery, 352
Disseminated intravascular coagulation
 in babesiosis, 1117
 in *Neisseria meningitidis* infections, protein C replacement in, 1338

DNA, synthesis, fluoroquinolone effects on, S9
DNA analysis
 for microorganisms in global resistance surveillance program, S156
 for *Pneumocystis carinii*, in immunocompetent infants, 855
 for tickborne diseases, 897
DNA gyrase, inhibition, fluoroquinolones in, S9
Doxycycline
 for brucellosis, 1024
 for cholera, 331
 for Lyme disease, 897
 for melioidosis, in cystic fibrosis, e15
 resistance to, *Enterococcus*, S133
 for *Rickettsia* infections, 897
Drug abuse, injection
 hepatitis B vaccination in, e143
 Staphylococcus aureus infections in, 581
Drug interactions, book reviews, 1245
Drug resistance (*see also* Susceptibility testing)
 Abiotrophia, e140
 Acinetobacter, global, S94, S156
 acyclovir, herpes simplex virus, 611
 albendazole, *Giardia lamblia*, 1792
 amikacin, 1162
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
 Stenotrophomonas maltophilia, S104
 amoxicillin, *Haemophilus influenzae*, S81
 ampicillin, *Enterococcus*, S133
 azithromycin, *Streptococcus pneumoniae*, S81
 aztreonam, *Pseudomonas aeruginosa*, S146
 Campylobacter fetus, 295
 Campylobacter jejuni, 1201
 Candida, 1554
 carbapenems, new β -lactamases and, 1085
 cefaclor, *Streptococcus pneumoniae*, S81
 cefepime
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
 cefotaxime, *Streptococcus pneumoniae*, 1463
 cefprozil, *Streptococcus pneumoniae*, S81
 ceftazidime
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
 Stenotrophomonas maltophilia, S104
 cefuroxime, *Streptococcus pneumoniae*, S81, 1463
 cephalosporins
 new β -lactamases and, 1085
 Salmonella, 263
chloramphenicol
 Enterococcus, S133
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 Streptococcus pneumoniae, S81, 1039
ciprofloxacin
 Acinetobacter, S104
 Enterococcus, S133
 Neisseria gonorrhoeae, 1313
 Pseudomonas aeruginosa, S146
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 Stenotrophomonas maltophilia, S104
clarithromycin, *Streptococcus pneumoniae*, S81
clindamycin
 Moraxella catarrhalis, S81
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 Streptococcus pneumoniae, S81

- coresistance patterns, global studies, S94
 cross-resistance, in quinolones, S1
 dichotomous, in quinolones, S1
 doxycycline, *Enterococcus*, S133
Enterobacteriaceae, global, S94, S156
enterococci, vancomycin, in hemodialysis, 23
Enterococcus
 global, S133, S156
 quinupristin-dalfopristin, coresistance patterns, S133
 vancomycin, 826, 1373, 1381
 bacteremia outcome and [letter and reply], 1110, 1112
 coresistance patterns, S133
erythromycin
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Streptococcus pneumoniae, S81
Escherichia coli
 extended-spectrum β -lactamase-producing, 1162
 global, S94, S156
 quinolones, S1
 extended-spectrum β -lactamase-producing organisms, global, S94, S156
fluconazole, *Candida*, 1554
fluoroquinolones, 162
Salmonella, 263
 theory, S39
ganciclovir, in transplantation, 742
gatifloxacin
Acinetobacter, S104
Enterococcus, S133
Pseudomonas aeruginosa, S146
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Stenotrophomonas maltophilia, S104
gentamicin, 1162
Acinetobacter, S104
Enterococcus, S133
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Giardia lamblia, 1792
 global context, 675 (see also SENTRY Antimicrobial Surveillance Program)
gram-negative organisms
 antibiotic therapy selection and, 1085
fluoroquinolones, 162
 global, S156
Haemophilus influenzae, global, S81
herpes simplex virus, acyclovir, 611
HIV, monitoring, 774
imipenem, 1162
Pseudomonas aeruginosa, S146
Streptococcus pneumoniae, 1463
ketoconazole, *Candida*, 1554
Klebsiella pneumoniae
 extended-spectrum β -lactamase-producing, 1162
 global, S94, S156
 β -lactamase-producing organisms
 antibiotic therapy selection and, 1085
 extended-spectrum, S94, S156
levofloxacin, 1162
Pseudomonas aeruginosa, S146
Streptococcus pneumoniae, 701
loracarbef, *Streptococcus pneumoniae*, S81
 mechanisms, in quinolones, S1
meropenem
Acinetobacter, S104
Pseudomonas aeruginosa, S146
Staphylococcus aureus (see *Staphylococcus aureus* infections, methicillin-resistant)
metronidazole, *Giardia lamblia*, 1792
 monitoring, clinical microbiology laboratory services in, 604, 605
monobactams, new β -lactamases and, 1085
Moraxella catarrhalis, global, S81
moxifloxacin, S16, S51
multiple
 global surveillance for, method in, S156
Streptococcus pneumoniae, 1463
 tuberculosis, 373
Neisseria gonorrhoeae
ciprofloxacin, 1313
fluoroquinolones, 884
nitrofurantoin, *Enterococcus*, S133
ofloxacin, 1162
Pantoea agglomerans, fluoroquinolones, 162
penicillin
Moraxella catarrhalis, S81
 new β -lactamases and, 1085
Streptococcus pneumoniae, S22, S81, 972, 1044
pharmacodynamic studies, S39
piperacillin
Acinetobacter, S104
Pseudomonas aeruginosa, S146
piperacillin-tazobactam
Acinetobacter, S104
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
Proteus mirabilis, S94
Pseudomonas aeruginosa
fluoroquinolones, 162
 global, S146, S156
quinolones, S1
quinupristin-dalfopristin, *Enterococcus*, coresistance patterns, S133
rifampin
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
 risk factors for, case-control studies, methodological principles, 1055
Salmonella
 global, S94
 nontyphoidal, 263
Staphylococcus, global, S114
Staphylococcus aureus
 methicillin (see *Staphylococcus aureus* infections, methicillin-resistant)
quinolones, S1
teicoplanin, 108
vancomycin, 108
Stenotrophomonas maltophilia, 1656 [letter]
 global, S104, S156
Streptococcus pneumoniae, 1039, 1463
fluoroquinolones, S39
 global, S81, S156
levofloxacin, 701
penicillin, S22, 972, 1044
quinolones, S1
vancomycin, 552
streptomycin, *Enterococcus*, S133
sulfamethoxazole, *Streptococcus pneumoniae*, 1039
sulfonamides, 1608
teicoplanin, *Staphylococcus aureus*, 108
tetracycline, 1162
Acinetobacter, S104
Staphylococcus, coagulase-negative, S114

- Staphylococcus aureus*, S114
Stenotrophomonas maltophilia, S104
Streptococcus pneumoniae, S81
ticarcillin, *Acinetobacter*, S104
ticarcillin-clavulanate
Acinetobacter, S104
Stenotrophomonas maltophilia, S104
tobramycin, 1162
Acinetobacter, S104
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
trimethoprim-sulfamethoxazole, 1162, 1608
Enterococcus, S133
Haemophilus influenzae, S81
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Streptococcus pneumoniae, S81
trovafloxacin
Acinetobacter, S104
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
tuberculosis, 159
multiple, clinical outcome, 373
use patterns and, 1189
vancomycin
Enterococcus, 826, 1373, 1381
bacteremia outcome and [letter and reply], 1110, 1112
coresistance patterns, S133
in hemodialysis, 23
Moraxella catarrhalis, S81
Staphylococcus aureus, 108
Streptococcus pneumoniae, 552
Dyspnea, in babesiosis, 1117
Ebola virus infections, nosocomial, prevention, 446
Echocardiography, in fungal endocarditis, 50
Economic issues
chronic venous disease, 949
cytomegalovirus infection prophylaxis, in HIV infection, 783
fellowship training on, adequacy of, 255
hip arthroplasty infections, 419
kidney failure in amphotericin B therapy, 686
nosocomial candidiasis [letter], 1100
pneumonia practice guidelines, 728
Eczema herpeticum, diagnosis, 1480, 1500
Editorials, case report policy, 1
Education
fellowship training survey, 255
in infectious disease, 752, 755
medical, clinical microbiology laboratory services in, 604, 605
patient, on infectious diarrhea prevention, 331
Edwardsiella tarda infections, myonecrosis, 1430
Efavirenz, resistance to, monitoring, 774
Eggs, *Salmonella enteritidis* infections due to, 890
Ehrlichiosis
hematologic counts during, 862
as nonspecific fever cause, 1434
review, 897
Elderly persons
coccidioidomycosis in, 708
herpes zoster in, 1481
hip arthroplasty infections in, treatment, 419
Streptococcus pneumoniae infections in, levofloxacin-resistant, 701
Electronic mail conference, on emerging infections, 270
Electrophoreses, pulsed-field gel, for microorganisms in global resistance surveillance program, S156
ELISA (*see* Enzyme-linked immunosorbent assay)
Emboli, in fungal endocarditis, 50
Emergency department
bacteremia diagnosis in, 559
blood diarrhea etiology in, 573
Chlamydia trachomatis infection diagnosis in, 103
gonorrhea diagnosis in, 103
pathologic studies in, 1589
Emerging infections
clinical microbiology laboratory services and, 604, 605
electronic mail conference and web page, 270
global context, 675
Whipple's disease, 457
Encephalitis
due to herpes simplex virus, vs. neurosyphilis, 1108
due to measles virus, in HIV infection, e57
due to *Mycoplasma pneumoniae*, in pediatric patients, 1674
due to sandfly fever virus serotype Toscana, 1241
subacute sclerosing, in American-born adult, 173
due to West Nile virus, outbreaks, New York City, 277
Encephalopathy
in HIV infection, 1487
Highly active antiretroviral therapy effects on, in pediatric patients, 464
spongiform
clinical implications, 1726
prevention, disinfection and sterilization for, 1348
Endocarditis
due to *Brucella*, skin lesions with, 63, 149
due to *Corynebacterium jeikeium*, after coronary angiography, e120
due to *Enterococcus*, vancomycin-resistant, treatment, 1373
due to fungi, literature review, 50
intravascular catheter-related, 1249
due to *Nocardia asteroides*, 660
prosthetic valve, due to *Staphylococcus hemolyticus*, e100
due to *Salmonella*, 263
due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
due to *Streptococcus pneumoniae*, penicillin-resistant, 972
Endometritis
due to *Staphylococcus aureus*, toxic shock syndrome in, 1470
treatment, Centers for Disease Control and Prevention guidelines, 103
Endophthalmitis, due to *Candida*, in neonates, 1018
Energy balance, in HIV infection, 1769
Entamoeba histolytica infections, diarrhea, practice guidelines, 331
Enterobacter cloacae infections, bacteremia, venous port-related, 1776
Enterobacteriaceae infections
bacteremia, emergency room management, 559
resistance in, global, S94, S156
Enterobacter infections, catheter-related, guidelines, 1249
Enterococcus casseliflavus/flavescens infections, bacteremia, 1540
Enterococcus faecium, as probiotic, 1381
Enterococcus faecium infections, resistance in, vancomycin, 1381
Enterococcus gallinarum infections, bacteremia, 1540
Enterococcus infections
bacteremia, mortality in, 587
catheter-related, guidelines, 1249
resistance in
global, S133, S156
quinupristin-dalfopristin, coresistance patterns, S133
vancomycin, 1381
bacteremia outcome and [letter and reply], 1110, 1112
coresistance patterns, S133
in hemodialysis, 23
prevention, 826
treatment, 1373

- Enterotoxins, staphylococcal, e53
 toxic shock syndrome due to, 1470
- Enterovirus infections, treatment with pleconaril, e13, 228
- Enterovirus 71 infections, neurological manifestations, in pediatric patients, 236
- Envenomation, spider, vs. infection, 595, 636
- Enzyme immunoassays, for *Toxoplasma gondii*, in schizophrenia, 842
- Enzyme-linked immunosorbent assay
 Gnathostoma spinigerum, e154
 as independent test [letter], 1114
 Pneumocystis carinii, in immunocompetent infants, 855
 Toxocara, e111
- Eosinophilia, in paragonimiasis, e171
- Epidemic typhus, meningitis in, 979
- Epidemiology (*see also* Outbreaks)
 adenovirus respiratory infections, in Korean children, 1423
 bacteremia, occult, 559
 basidiobolomycosis, gastrointestinal, Arizona, 1448
 Campylobacter jejuni infections, 1201
 chronic venous disease, 949
 Creutzfeldt-Jacob disease, 1348
 cyclosporiasis, Missouri, 1010
 diarrhea, 331
 bloody, 573
 Enterococcus casseliflavus/flavescens bacteremia, 1540
 Enterococcus gallinarum bacteremia, 1540
 global context, 675
 Helicobacter pylori infections, breast-feeding practices and, 1387
 herpes zoster, in elderly persons, 1481
 HIV infection
 East Timor, 991
 Thailand, 955
 influenza, Current News, May 1
 intravascular catheter-related infections, 1249
 leprosy, in United States immigrants, 930
 malaria, Georgia, e124
 melioidosis, Laos, 653
 meningitis, in pediatric patients, in Africa, 64
 Neisseria meningitidis infections, in pediatric patients, in Massachusetts, 1004
 pertussis, in elderly persons [letter], 847
 pneumonia, Finland, 1141
 prion diseases, 1726
 Salmonella enteritidis infections, phage type 4, Caribbean, 890
 sexually transmitted diseases, travelers' risk and, 1063
 Staphylococcus aureus, vancomycin-resistant, 108
 tickborne diseases, 897
 travel diseases, information resources for, 757
 tuberculin test reactivity, in hospital physicians, 1331
 tuberculosis, Internet resources on, 1580
 West Nile viral encephalitis, New York City, 277
 zoonotic diseases, nosocomial, 446
- Epidural abscess, spinal, in pediatric patients, 9
- Epstein-Barr virus infections, chronic fatigue syndrome in [letter], 1657
- Errata
- aspergillosis (2000;31:1524), 673
- CHAT oral polio vaccine (2001;32:1068), 1386
- chronic fatigue syndrome and fibromyalgia, resources for (2001;32: 938), 1803
- cryptococcosis (2000;31:1303), 175
- cryptosporidiosis, paramomycin in (2001;32:1516), 1803
- cutaneous larva migrans (2000;31:493), 523
- disseminated *Mycobacterium avium* infection, treatment of (2000;31: 1245), 1386
- foodborne listeriosis (2000;31:770), 1803levofloxacin-resistant *Streptococcus pneumoniae* (2001;32:701), 1247
- Mycobacterium avium* infection treatment (2000;31:1245), 1386
- nasal carriage or organisms (2000;31:875), 176
- protein C replacement, in severe meningococcemia (2001;32:1338), 1803
- strongyloidiasis (2000;31:e5), 176
- toxoplasmosis (2001;32:842), 1247
- Erythema nodosum leprosum, in immigrants, 930
- Erythromycin
 for *Campylobacter jejuni* infections, 1201
 for diarrhea, 331
 resistance to
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
- Erythropoietin, for HIV infection, 766
- Escherichia coli*, in vaginal flora, e69
- Escherichia coli* infections
 catheter-related, guidelines, 1249
 diabetic ketoacidosis in, 30
 diarrhea
 epidemiology, 573
 practice guidelines, 331
 enteroaggregative, in travelers' diarrhea, 1706, 1710
 O157:H7, diarrhea, epidemiology, 573
 pneumonia, lung tap for, 715
 resistance in
 extended-spectrum β -lactamase-producing, 1162
 global, S94, S156
 quinolones, S1
 sulfonamides, 1608
 trimethoprim-sulfamethoxazole, 1608
- Shiga toxin-producing
 diarrhea, epidemiology, 573
 testing for [letter], 1517
- T lymphocyte type 1/type 2 immunity in, 76
- virulence factors, in urinary tract infections, 1523
- Estrogens, in T lymphocyte type 1/type 2 immunity, 76
- Ethambutol, for *Mycobacterium avium* complex infections, 1547
- Ethical issues, in fellowship acceptance, 752, 755
- Ethnic factors
 in coccidioidomycosis susceptibility, 708
 in *Helicobacter pylori* infection epidemiology, 1387
 in *Streptococcus pneumoniae* infections, in HIV infection, 794
- EuroQol Group questionnaire, in HIV infection quality-of-life measurement, e47
- Exercise, in HIV infection, 1769
- Eye infections
 due to *Candida*, in neonates, 1018
 due to cytomegalovirus, after stem cell transplantation, 214
 due to *Treponema pallidum*, 1661
- Famciclovir
 for herpes simplex virus infections, in HIV infection, 611
 for herpes zoster, 1481
- Fasciitis, necrotizing, due to β -hemolytic streptococci, laboratory tests for, e9
- Fasciola hepatica* infections, liver, 727, 820, 1658 [letter]
- Fat, body, distribution of, in HIV infection, 130
- Fatigue, chronic
 information resources for, 938
 treatment with antiviral agents [letter], 1657
- Fat redistribution, due to HIV therapy, 1769
- Fellowship programs
 in infectious disease, 752, 755
 survey of recent graduates, 255
- Ferritin, as HIV severity marker, 1496

- Fever
 blackwater, in malaria, 1133
 dengue hemorrhagic
 microvascular leakage in, noninvasive measurement, 243
 treatment, 204
 interval of, in meningitis, in pediatric patients, 566
 in malaria, treatment, 838
 Mediterranean spotted, review, 897
 meningococcal vaccines, 1273
 in neutropenia
 in cancer
 gram-negative bacteremia prediction in, 832
 treatment, in children, 36
 empirical antifungal therapy for [letter and reply], 320, 518
 treatment, 381
 in occult bacteremia, emergency department management, 559
 relapsing, review, 897
 of unknown origin
 positron emission tomography in, 191
 tickborne infections in, 1434
 Fibromyalgia, information resources for, 938
 Finger(s), acrodermatitis continua of Hallopeau, 431, 505
 Fluconazole
 for *Candida lusitaniae* infections, 186
 for *Cryptococcus neoformans* infections, in cancer, e145
 for fever, in neutropenia [letter and reply], 320, 518
 for histoplasmosis, in HIV infection, 483
 for intravascular catheter-related infections, 1249
 for osteomyelitis, due to *Candida*, 527
 prophylactic
 in intensive care unit, 1191
 for neutropenia, bacteremia breakthrough in, 1532, 1538
 resistance to, *Candida*, 1554
 for urinary tract infections, due to *Candida*, 1602
 Flucytosine
 for endocarditis, 50
 for osteomyelitis, due to *Candida*, 527
 Fluid therapy, for dengue hemorrhagic fever, 204
 Flukes, liver, 727, 820
 Fluorescent antibody staining, for herpes simplex virus, in HIV infection, 611
 Fluoro-deoxyglucose, fluorine-labeled, in positron emission tomography, in fever of unknown origin, 191
 Fluoroquinolones
 for diarrhea, 331
 for intravascular catheter-related infections, 1249
 mechanisms of action, S9
 resistance to, 162
 cross-resistance and dichotomous, S1
 Neisseria gonorrhoeae, 884
 Salmonella, 263
 for respiratory infections, S64
 toxicity, S72
 Foodborne diseases
 due to *Campylobacter jejuni*, epidemiology, 1201
 clinical microbiology laboratory services and, 604, 605
 due to *Cyclospora*, outbreaks, 1010
 diarrhea in, practice guidelines, 331
 due to *Gongylonema*, 1378
 due to *Listeria monocytogenes*, treatment [letter and reply], 1518, 1519
 due to *Salmonella*, nontyphoidal, 263
 due to *Salmonella enteritidis*, phage type 4, 890
 trichinosis
 T lymphocyte type 1/type 2 immunity in, 76
 treatment failure, 638
 Foscarnet
- for cytomegalovirus infections, retinitis, 214
 for herpes simplex virus, in HIV infection, 611
Francisella tularensis infections, review, 897
 Fungal infections (*see also specific infections*)
 catheter-related, guidelines, 1249
 endocarditis, literature review, 50
 invasive, in bone marrow transplantation, 1319
 in neutropenia, empirical antifungal therapy for [letter and reply], 320, 518
 pathology, 1589
 prophylaxis
 in intensive care unit, 1191
 in neutropenia, bacteremia breakthrough and, 1532, 1538
 T lymphocyte type 1/type 2 immunity in, 76
 treatment, guidelines for [letter], 321
 Fungemia
 due to *Candida*, in neonates, 1018
 due to *Candida lusitaniae*, 186
Fusarium infections, in heart-liver transplantation, 1237
Fusobacterium nucleatum infections, liver abscess, in lymphocytopenia [letter], 326
 Gabapentin, for herpes zoster, 1481
 Gallium scintigraphy, in fever of unknown origin, 191
 Ganciclovir
 for chronic fatigue syndrome [letter], 1657
 for cytomegalovirus infections, 313
 prophylactic, 596
 retinitis, 214
 in transplantation, 742
 resistance to, in transplantation, 742
Gardnerella vaginalis, in normal flora, e69
 Gastrointestinal infections
 due to *Basidiobolus*, 1448
 due to *Campylobacter fetus*, in HIV infection, 295
 due to *Campylobacter jejuni*, epidemiology, 1201
 due to *Histoplasma capsulatum*, in HIV infection, 483
 practice guidelines, 331
 due to rotavirus, severity, vs. viral strain, 1126
 due to *Salmonella*, nontyphoidal, 263
 due to *Tropheryma whippelii*, 457
 Gastrointestinal tract
 bleeding in, in HIV infection, 1487
 fluoroquinolone-resistant bacteria in, 162
 fluoroquinolone toxicity to, S72
 Gatifloxacin
 mechanisms of action, S9
 pharmacodynamics, S39
 resistance to
 Acinetobacter, S104
 Enterococcus, S133
 Pseudomonas aeruginosa, S146
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 Stenotrophomonas maltophilia, S104
 Gel, alcohol-based, for hand cleansing, artificial fingernail colonization and, 367
 Genetic factors, in infections, 675
 Genital tract infections
 due to herpes simplex virus, in HIV infection, 611
 in HIV infection, 611
 due to *Mycobacterium tuberculosis*, after kidney transplantation, 662
 due to *Staphylococcus aureus*, toxic shock syndrome in, 1470
 upper, treatment, Centers for Disease Control and Prevention guidelines, 103
 Genotyping, in drug resistance detection, in HIV infection, 774

- Gentamicin
for brucellosis, 506
for intravascular catheter-related infections, 1249
resistance to, 1162
Acinetobacter, S104
Enterococcus, S133
extended-spectrum β -lactamase-producing organisms, S94
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
for tuberculosis, refractory, 44
Geriatric patients (*see* Elderly persons)
Giant cell pneumonia, due to measles virus, in HIV infection, e57
Giardiasis
in HIV infection, 1792
practice guidelines, 331
Global Infectious Disease and Epidemiology Network, for travel medicine information, 757
Global view, of infectious diseases, 675
Glomerulonephritis, in parvovirus B19 infections, 167
Gloves, for vancomycin-resistant *Enterococcus* control, 826
Glucose, metabolism of, in HIV infection, 130
Gnathostomiasis, medullary, e154
Gongylonema infections, oral cavity, 1378
Gonococcal infections (*see* *Neisseria gonorrhoeae* infections)
Good's syndrome, adult-onset [letter], 323
Gram-negative infections
area under inhibitory concentration curve values, S39
resistance in, 1085
fluoroquinolones, 162
global, S156
Gram-positive infections
area under inhibitory concentration curve values, S39
moxifloxacin for, S16
Gram stain, for infection diagnosis, 1589
Granulocyte colony-stimulating factor, for HIV infection, 766, 1738
Granulocyte-macrophage colony-stimulating factor
for HIV infection, 766, 1738
for rhinocerebral zygomycosis, e166
Granulomas, pathology, 1589
Grepafloxacin
resistance to, S1
toxicity, S72
Guidelines
development, 851
fungal infections [letter], 321
infectious diarrhea, 331
intravascular catheter-related infections, 1249
pelvic inflammatory disease, 103
penicillin skin testing, 1685
pneumonia, cost-effectiveness, 728
Guillain-Barré syndrome
due to *Campylobacter jejuni*, 1201
due to enterovirus 71, 236
due to meningococcal vaccines, 1273
HAART (*see* Highly active antiretroviral therapy)
Haemaphysalis species, review, 897
Haemophilus aphrophilus, misidentification [letter and reply], 987, 989
Haemophilus influenzae, in vaginal flora, e69
Haemophilus influenzae infections
epidemiology, in pediatric patients, in Africa, 64
fever interval in, in pediatric patients, 566
pneumonia
in Finland, 1141
lung tap for, 715
resistance in
global, S81
trimethoprim-sulfamethoxazole, 1608
T lymphocyte type 1/type 2 immunity in, 76
treatment, moxifloxacin, S51, S64
vaccination
antibody measurement after, 2
failure, 1700
Hallopeau, acrodermatitis continua of, digital, 431, 505
Haloantrine, blackwater fever due to, 1133
Hand cleansing methods, artificial fingernail colonization and, 367
Hantavirus infections, nosocomial, prevention, 446
Headache, meningococcal vaccines, 1273
Hearing loss, nucleoside analog reverse transcriptase inhibitors, 1623
Heart (*see also* Endocarditis)
candidiasis, in neonates, 1018
failure
in babesiosis, 1117
in HIV infection, 1487
fluoroquinolone effects on, S72
myocarditis, due to *Coxiella burnetii*, 1440
Q fever effects on, 1440
transplantation
cytomegalovirus infections in, prevention, 742
pneumococcal vaccination in, 307
Heart-liver transplantation, *Fusarium* infections in, 1237
Helicobacter pylori infections
asymptomatic, breast-feeding practices and, 1387
pathology, 1589
resistance in, sulfonamides, 1608
Helmintic infections, T lymphocyte type 1/type 2 immunity in, 76
Hematoxylin and eosin stain, for infection diagnosis, 1589
Hemodialysis
catheter-related infections in, guidelines, 1249
vancomycin-resistant organism acquisition in
Enterococcus, 23
Staphylococcus aureus, 108
Hemoglobin
as HIV severity marker, 1496
measurement, in ehrlichiosis, 862
Hemoglobinuria, in malaria, 1133
Hemolysis, in malaria, 1133
Hemolytic uremic syndrome, Shiga toxin testing in [letter], 1517
Hemorrhagic cystitis, in bone marrow transplantation, due to adenovirus, 1325
Hemorrhagic fever
dengue
microvascular leakage in, noninvasive measurement, 243
treatment, 204
nosocomial, prevention, 446
Hepatitis, T lymphocyte type 1/type 2 immunity in, 76
Hepatitis A
in HIV infection, 297
vaccination
boosters, 396
in liver transplantation [letter], 1656
Hepatitis B
in HIV infection, reactivation, 144
vaccination
in injection drug users, e143
in travelers, 1063
Hepatitis C
cryptococcosis with, myositis in, 1104
hepatopulmonary syndrome in, treatment, e131
in HIV infection
lamivudine effects on, 963
mortality in, 492, 1207

- treatment, amantadine, 830
- Hepatocellular carcinoma, in hepatitis C, in HIV infection, 1207
- Hepatopulmonary syndrome, treatment, e131
- Herpes simplex virus infections
- in bone marrow or stem cell transplantation, 546
 - encephalitis, vs. neurosyphilis, 1108
 - as histoplasmosis risk factor, in HIV infection, 1215
 - in HIV infection, 611
 - pathology, 1589
 - resistance in, acyclovir, 611
 - skin manifestations, 1480, 1500
- Herpes zoster
- in elderly persons, 1481
 - after stem cell transplantation, 1414
- Highly active antiretroviral therapy, for HIV infection
- hepatitis B reactivation in, 144
 - immune response in, 1738
 - leishmaniasis and, 633
 - measles vaccination response, 1090
 - nutrition and, 1769
 - parvovirus B19-induced anemia resolution in, e122, 1361
 - in pediatric patients, 464
- Hip arthroplasty, infections, treatment, 419
- Histiocytosis, due to *Campylobacter fetus*, in HIV infection, 295
- Histoplasmosis
- endocarditis in, literature review, 50
 - in HIV infection
 - gastrointestinal, 483
 - risk factors for, 1215 - pathology, 1589
- HIV infection (see Human immunodeficiency virus infection)
- Human granulocytic ehrlichiosis
- hematologic counts during, 862
 - as nonspecific fever cause, 1434
 - review, 897
- Human herpesvirus type 6 infections
- recurrent, in multiple organ failure syndrome, 197
 - in transplantation, 1357
- Human herpesvirus type 7 infections, in transplantation, 1357
- Human herpesvirus type 8 infections
- in kidney allografts, Kaposi's sarcoma development, 1502
 - sarcoidosis and, 1100
- Human immunodeficiency virus infection
- acute (see Human immunodeficiency virus infection, primary)
 - antibodies in, 1756
 - Aspergillus* infections in, mortality in, 358
 - avascular necrosis in, 1221
 - bacteremia in, due to venous access port, 1776
 - Campylobacter fetus* infection in, 295
 - Candida dubliniensis* infections in, 1034
 - candidiasis in, oropharyngeal, 1554
 - cardiovascular risks in, 130
 - Chlamydia trachomatis* infections in, 611
 - screening for, 808
 - clinical features, in Thailand, 955
 - cryptococcosis in
 - antigen detection in, false-negative results in, 836
 - meningitis, 955
 - myelitis, 1235 - cytomegalovirus infections in
 - antibiotic prophylaxis for, 116
 - retinitis, 815
 - treatment, Current News, May 1 - dual *Pneumocystis carinii* infection and tuberculosis in, 289
 - epidemiology, 675
 - East Timor, 991
 - Thailand, 955
 - giardiasis in, 1792
 - gonorrhea in, 611
 - hepatitis A in, 297
 - hepatitis B in, reactivation, 144
 - hepatitis C in
 - lamivudine effects on, 963
 - mortality in, 492 - herpes simplex virus infections in, 611
 - histoplasmosis in
 - gastrointestinal, 483
 - risk factors for, 1215 - immunopathogenesis, 1738
 - influenza in
 - outbreaks, 1784
 - progression after, 1366 - Kawasaki-like syndromes in, 1628
 - leishmaniasis in, highly active antiretroviral therapy effects on, 633
 - lipodystrophy in, 130
 - liver disease in, mortality in, 492
 - lymphoma in, acyclovir and [letter], 989
 - measles in, e57
 - meningitis in, due to *Cryptococcus neoformans*, 836, 955
 - metabolic abnormalities in, 130
 - mortality, changing spectrum, 1487
 - Mycobacterium abscessus* infections in, 432
 - Mycobacterium avium* complex infections in
 - antibiotic prophylaxis for, 116
 - prophylaxis, 1615
 - treatment, e81 - Mycoplasma genitalium* infections in, 611
 - myelitis in, due to *Cryptococcus neoformans*, 1235
 - neutropenia in, natural history, 469
 - new infections in, 432
 - non-B subtype
 - transmission by travelers, 1732
 - virus load measurement in, 1227 - nonprogression, natural history, 1756
 - oral cavity infections in, due to *Candida*, 1554
 - parvovirus B19 infections in, e122, 1361
 - pathogenesis, 1738, 1756
 - in pediatric patients (see Pediatric patients, human immunodeficiency virus infection in)
 - penicilliosis in, e78
 - Penicillium marneffei* infections in, 955
 - Pneumocystis carinii* infections in, 955
 - disseminated, 254, 300
 - thoracic, 498
 - tuberculosis with, 289 - pneumonia in, due to measles virus, e57
 - in pregnancy, iron status and, 1496
 - prevention
 - hypercholesterolemia in, 1635
 - postexposure prophylaxis, 1494
 - probiotics in, 1567, 1577
 - vaginal microbicides in, 476 - primary
 - clinical features, 1756
 - natural history, 1756
 - rhabdomyolysis in, 502
 - treatment, 1738
 - cerebrospinal fluid RNA measurement, 1095 - progression, 1756
 - after influenza, 1366 - quality of life in, measurement, e524
 - resistance in, detection, 774

- retinitis in, due to cytomegalovirus, 815
 treatment, Current News, May 1
- Rhodococcus equi* infections in, e39, 929, 970
- risk factors, in Thailand, 955
- Salmonella* infections in, 263
- Scedosporium prolificans* infections in, e158
- sexually transmitted diseases in, 611
 screening for, 808
- Staphylococcus aureus* infections in, methicillin-resistant, in injection drug users, 581
- Streptococcus pneumoniae* infections in, 794
 in pediatric patients, 1155
- syphilis in, 611, 667
- T lymphocytes in (see *T lymphocytes*, in HIV infection)
transmission
 polio vaccine hypothesis, 1068
 prevention, 1494
 probiotics in, 1567, 1577
 vaginal microbicides in, 476
 between primate species, 1068
 by travelers, 1732
- treatment (see also Highly active antiretroviral therapy; specific drugs)
 complications, 124
 drug resistance in, 774
 with hepatitis C, 963
 immune-based, 1738, 1756
 immune restoration in [letter], 325
 measles vaccination response, 1090
 neutropenia due to, 469
 nutritional problems in, 1769
 ototoxicity in, 1623
 paronychia in, 140
 parvovirus B19 infection resolution in, e122
 in pediatric patients, 464
 primary, 1095
 spinal epidural lipomatosis due to, e90
 virologic rebound in, 1231
- trichomoniasis in, 611
 screening for, 808
- tuberculosis in
 chemokine receptor expression in, 650
 multidrug-resistant, 159
- Pneumocystis carinii* infections with, 289
- recurrence, 515
- in Thailand, 955
 treatment, 321 [letters and reply], 623
- Ureaplasma urealyticum* infections in, 611
- urethritis in, 611
- vaccination, in neonates, 801
- virus load in
 vs. iron status, 1496
 treatment effects on, 1738
- wasting in antibiotic prophylaxis in, 116
- weight management in, 1769
- Human monocytic ehrlichiosis, review, 897
- Human papillomavirus infections
 in HIV infection, 611
 pathology, 1589
 respiratory, treatment with cidofovir, e62
- Human parvovirus B19 infections (see Parvovirus B19 infections)
- Human T cell lymphotropic/leukemia virus type 1 infections, myelopathy associated with, inclusion body myositis in, 510
- Humoral immune response, T lymphocytes in, type 1/type 2 immunity, 76
- Hyalomma* species, review, 897
- Hydatidosis, of thigh muscle, treatment, e65
- Hydrogen peroxide, produced by viridans streptococci, in methicillin-resistant *Staphylococcus aureus* colonization, in newborns, 1408
- Hydroxyurea, for HIV infection, 1738
- Hypercholesterolemia
 in HIV infection, 130
 due to HIV prophylaxis, 1635
- Hypersensitivity
 delayed, pathogenesis, e17
 to fluoroquinolones, S72
- Hypertension, in HIV infection, 130
- Hypertriglyceridemia, in HIV infection, 130
- Hypogammaglobulinemia, in Good's syndrome, adult-onset [letter], 323
- Hypopituitarism, immunodeficiency in, 153
- Hypotension, in *Neisseria meningitidis* infections, in pediatric patients, 1004
- IDSA (see Infectious Diseases Society of America)
- IFN- α (see Interferon- α)
- IFN- γ (see Interferon- γ)
- IL(s) (see Interleukin[s])
- Imipenem
 for febrile neutropenia, 381
 for intravascular catheter-related infections, 1249
 resistance to, 1162
- Pseudomonas aeruginosa*, S146
- Streptococcus pneumoniae*, 1463
- Imiquimod, for human papillomavirus infections, 611
- Immune complexes, pneumolysin antibody detection in, 534
- Immune globulin, for Kawasaki-like syndromes, in HIV infection, 1628
- Immune response
 HIV, 1738, 1756
 pathology of, 1589
 T lymphocytes in, type 1/type 2 immunity, 76
- Immune system, reconstitution, mycobacterial infections and [letter and reply], 845, 846
- Immunization (see Vaccines and vaccination)
- Immunoblot assay, as independent test [letter], 1114
- Immunodeficiency (see also Human immunodeficiency virus infection; Neutropenia; Transplantation)
Aspergillus infections in, mortality in, 358
- Bacillus cereus* infections in, in pediatric patients, 1456
- Enterococcus* bacteraemia in, 1540
- enterovirus infections in, treatment with pleconaril, e13
- in panhypopituitarism, 153
- Salmonella* infections in, 263
- Scedosporium prolificans* infections in, e158
- Immunofluorescence test
 for parainfluenza virus, 413
 for rickettsiae, 897
- Immunoglobulin(s)
 in paragonimiasis, e171
 therapeutic (see Immune globulin)
- Immunoglobulin G, pneumolysin, assays for, 534
- Immunohistochemistry, for infection diagnosis, 1589
- Immunosuppressive therapy
 for HIV infection, 1738
- Immunotherapy
 for HIV infection, 1738
- Salmonella* infections related to, 263
- T lymphocyte type 1/type 2 immunity and, 76
- Inclusion body myositis, in human T cell leukemia virus type 1 virus-associated myopathy, 510
- Indinavir, for HIV infection, paronychia in, 140
- Infarction, brain, in *Mycoplasma pneumoniae* infections, e31
- Infection control
 artificial nails and, 352, 367
- Creutzfeldt-Jacob disease, 1348

- fellowship training on, adequacy of, 255
mask aversion and [letter], 991
prion diseases, 1726
in simulated bioterrorist attack, 436
tickborne diseases, 897
for vancomycin resistance prevention, 108
vancomycin-resistant *Enterococcus*, 826
zoonotic diseases, 446
- Infectious Diseases Society of America
guidelines
development, 851
infectious diarrhea, 331
intravascular catheter-related infections, 1249
lecture at 2000 annual meeting, 675
policy statement, on consolidation of clinical microbiology laboratories, 604, 605
training program, 755
- Influenza
epidemiology, Current News, May 1
in HIV infection
outbreaks, 1784
progression after, 1366
outbreaks
in HIV infection, 1784
from imported virus, 1639
pandemic, potential for, 675
vaccination, in HIV infection, 1784
- Information resources, Internet (see Internet resources)
- In situ hybridization test, for infection diagnosis, 1589
- Insulin resistance, in HIV infection, 130
- Intensive care unit
diabetic ketoacidosis in, infection as trigger, 30
gram-negative infections in, in neonates, 220
prophylactic antifungal therapy in, 1191
- Interferon- α , for HIV infection, 1738
- Interferon- γ
for brain abscess, due to *Aspergillus*, e137
for *Mycobacterium avium* complex infections, in HIV infection, e81
T lymphocyte type 1/type 2 immunity and, 76
- Interleukin(s)
for HIV infection, 1738, 1756
T lymphocyte type 1/type 2 immunity and, 76
- Interleukin-2, for HIV infection, 766
- Interleukin-8, in gram-negative bacteremia prediction, in neutropenia, 832
- International-Infectious Disease Society for Obstetric and Gynecology—USA, on Centers for Disease Control and Prevention pelvic inflammatory disease guidelines, 103
- Internet resources
emerging infections, 270
travel medicine, 757
tuberculosis, 1580
- Intracranial hypertension, in enterovirus 71 infections, 236
- Iron status, as HIV severity marker, 1496
- Isosporiasis, practice guidelines, 331
- Itraconazole
for alternariosis, in diabetes mellitus, 1178
for aspergillosis, in bone marrow transplantation, e94
for basidiobolomycosis, 1448
for brain abscess, due to *Aspergillus*, e137
for histoplasmosis, in HIV infection, 483
for lymphadenitis, due to *Scedosporium apiospermum*, e59
- Ixodidae (hard ticks), review, 897
- Janeway lesions, due to *Brucella* endocarditis, 63, 149
- Jaundice, in malaria, 1133
- JC virus infections
- in bone marrow transplantation, 1325
treatment, failure, 150
- Joint infections
prosthetic, hip, treatment, 419
due to *Staphylococcus aureus*, 647
- Juvenile rheumatoid arthritis, *Bartonella* infections in, e22
- Kala-azar (see Leishmaniasis, visceral)
- Kanamycin, for refractory tuberculosis, 44
- Kaposi's sarcoma
after kidney transplantation, 1502
Kaposi's disease with, virus detection in, 1100
- Kawasaki disease, in HIV infection, 1628
- Kenyon stain, for infection diagnosis, 1589
- Keratinocytes, *Staphylococcus aureus* persistence in, 1643
- Ketoacidosis, diabetic, infection as trigger, 30
- Ketoconazole
for intravascular catheter-related infections, 1249
prophylactic, in neutropenia, bacteremia breakthrough and, 1532, 1538
resistance to, *Candida*, 1554
- Kidney
dysfunction and failure
in amphotericin B toxicity, 686, 990 [letter]
in babesiosis, 1117
in candidiasis, in neonates, 1018
in fluoroquinolone toxicity, S72
in HIV infection, 1487
Highly active antiretroviral therapy effects on, in pediatric patients, 464
in malaria, 1133
- Infections
due to *Candida*, 1602
due to parvovirus B19, 167
- transplantation
cytomegalovirus infections in, prevention, 742
genitourinary tuberculosis after, 662
human herpesvirus 6 and 7 infections in, 1357
human herpesvirus 8 detection, Kaposi's sarcoma development, 1502
- Klebsiella pneumoniae* infections, resistance in
extended-spectrum β -lactamase-producing, 1162
- global, S94, S156
trimethoprim-sulfamethoxazole, 1608
- Koprowski hypothesis, for HIV transmission in poliovirus vaccine, 1068
- Kuru, clinical implications, 1726
- Laboratories, clinical microbiology, consolidation, Infectious Diseases Society of America policy statement on, 604, 605
- β -Lactamases
extended-spectrum, 1162
global resistance studies, S94, S156
new, antibiotic therapy selection and, 1085
- Lactobacillus*, vaginal, e69
variation during menstrual cycle [letter], 325
- Lactobacillus* infections, T lymphocyte type 1/type 2 immunity in, 76
- Lactobacillus rhamnosus*, as probiotic, 1567, 1577
- Laminectomy, *Candida* infections after, 352
- Lamivudine
for HIV infection
with hepatitis C, 963
prophylactic, 1494
resistance to, monitoring, 774
- Larynx, papillomatosis in, due to human papillomavirus, treatment with cidofovir, e62
- Lassa fever, nosocomial, prevention, 446
- Leclercia adecarboxylata* infections, in pediatric patients [letter], 1659

- Legionella infections**
 pathology, 1589
 pneumonia, treatment failure, 1562
- Leishmaniasis**
 cutaneous, *braziliensis* vs. *guyanensis*, 1304
 T lymphocyte type 1/type 2 immunity in, 76
 visceral
 in HIV infection, highly active antiretroviral therapy effects on, 633
 without endemic area exposure, 302
- Leprosy**
 in immunorestitution disease [letter and reply], 845, 846
 T lymphocyte type 1/type 2 immunity in, 76
 in United States immigrants, 930
- Leukemia**
Candida lusitaniae infections in, 186
 cytomegalovirus infections in, 539
Leclercia adecarboxylata infections in [letter], 1659
Scedosporium prolificans infections in, e158
- Leukocyte counts**, during human granulocytic ehrlichiosis, 862
- Leukocyte infusion**, for adenovirus infections, in stem cell transplantation, 1290
- Leukoencephalopathy**, progressive multifocal, treatment, failure, 150
- Leukopenia**, in ehrlichiosis, 862
- Leukotrienes**, T lymphocyte type 1/type 2 immunity and, 76
- Levofoxacin**
 for meningitis, tuberculous, 643
 pharmacodynamics, S39
 staphylococcal infections, S33
 resistance to, 1162
 Pseudomonas aeruginosa, S146
 Streptococcus pneumoniae, 701
 for respiratory infections, S39
 toxicity, S72
- Lidocaine**, for herpes zoster, 1481
- Linezolid**
 for endocarditis, due to *Enterococcus*, 1373
 for intravascular catheter-related infections, 1249
 for pneumonia, nosocomial, 402
- Lipodystrophy**, in HIV infection, 130
- Lipomatosis**, spinal, due to corticosteroids, e90
- Listeriosis**
 foodborne, treatment [letter and reply], 1518, 1519
 resistance in, trimethoprim-sulfamethoxazole, 1608
 T lymphocyte type 1/type 2 immunity in, 76
- Liver**
 abscess
 due to *Brucella*, 1024
 due to *Fusobacterium nucleatum* [letter], 326
 disorders
 due to amphotericin B lipid formulations, e87
 due to *Babesia*, 1117
 due to *Candida*, in neonates, 1018
 due to *Fasciola hepatica*, 727, 820, 1658 [letter]
 due to fluoroquinolones, S72
 in HIV infection, 1487
 mortality in, 492, 1207
 transplantation
 cytomegalovirus infections in, prevention, 742
 hepatitis A vaccination in [letter], 1656
 human herpesvirus 6 and 7 infections in, 1357
- Loracarbef**, resistance to, *Streptococcus pneumoniae*, S81
- Lumbar puncture**, mask use in, aversion to [letter], 991
- Lung** (see also Pneumonia; Tuberculosis)
 aspiration from, for pneumonia diagnosis, in pediatric patients, 715
 cancer, *Legionella* infections in, treatment failure, 1562
 fibrosis, in ankylosing spondylitis, 1062, 1103
- transplantation, cytomegalovirus infections in, 742
- Lyme disease**
 as nonspecific fever cause, 1434
 review, 897
- Lymphadenitis**
 due to *Burkholderia pseudomallei*, 653
 due to *Scedosporium apiospermum*, e59
- Lymphangitis**
 due to *Leishmania*, *braziliensis* vs. *guyanensis*, 1304
 sporotrichoid, due to *Streptococcus* group A, e176
- Lymphocytopenia**
 in ehrlichiosis, 862
 liver abscess in, due to *Fusobacterium nucleatum* [letter], 326
- Lymphoma**
Candida lusitaniae infections in, 186
 in HIV infection, acyclovir and [letter], 989
- Mad cow disease**
 clinical implications, 1726
 prevention, disinfection and sterilization for, 1348
- Magnetic resonance imaging**, of spinal cord gnathostomiasis, e154
- Malaria**
 epidemiology, Georgia, e124
 due to *Plasmodium falciparum*
 blackwater fever in, 1133
 treatment, in pediatric patients, 838
- Malassezia furfur** infections, catheter-related, guidelines, 1249
- Marburg virus infections**, nosocomial, prevention, 446
- Masks**, in lumbar puncture, aversion to [letter], 991
- Measles**
 giant cell pneumonia in, in HIV infection, e57
 subclinical, subacute sclerosing panencephalitis in, 173
 vaccination, in HIV infection, highly active antiretroviral therapy effects on, 1090
- Mebendazole**, for trichinosis, failure, 638
- Mediastinitis**, due to *Staphylococcus aureus*, methicillin resistance and, 877
- Medical Letter, The**, for travel medicine information, 757
- Medical Outcomes Study**, in HIV infection quality of life measurement, e47
- Medicare**, pneumonia overcharges, Current News, May 15
- Mediterranean spotted fever**, review, 897
- Medulla**, spinal cord, gnathostomiasis, e154
- Mefloquine**, blackwater fever due to, 1133
- Megestrol acetate**, for wasting, in HIV infection, 116
- Melioidosis**
 in cystic fibrosis, e15
 epidemiology, Laos, 653
- Meningitis**
 aseptic
 due to enterovirus 71, 236
 after neurological surgery, vs. bacterial meningitis, 179
 due to *Bacillus cereus*, in immunodeficiency, in pediatric patients, 1456
 due to *Cryptococcus neoformans*
 in cancer, e145
 in HIV infection, 836
 epidemiology, in pediatric patients, in Africa, 64
 fever interval in, in pediatric patients, 566
- Mollaret's**, pathology, 1589
- due to *Mycoplasma pneumoniae*, e31
- due to *Neisseria meningitidis*, epidemiology, 1004
- due to *Rickettsia prowazekii*, 979
- due to *Streptococcus pneumoniae*, serogroups, in pediatric patients, 1155
- tuberculous, treatment, 643

- Meningococcal infections
 epidemiology, in pediatric patients
 in Africa, 64
 in Massachusetts, 1004
 meningitis, fever interval in, in pediatric patients, 566
 risk factors, invasive, in school workers, 1795
 vaccination
 intramuscular vs. subcutaneous, 170
 safety data, 1273
- Meningoencephalitis, in *Mycoplasma pneumoniae* infections, e31
- Menstrual cycle, vaginal microflora variation during [letter], 325
- Meropenem, resistance to
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
- Metallo- β -lactamases, antibiotic therapy selection and, 1085
- Metamizol, for malaria, in pediatric patients, 838
- Methicillin, resistance to
 coagulase-negative *Staphylococcus*, S114
 Staphylococcus aureus (see *Staphylococcus aureus* infections, methicillin-resistant)
- Methylprednisolone
 for herpes zoster, 1481
 in T lymphocyte type 1/type 2 immunity, 76
- Metronidazole
 for diarrhea, 331
 for histoplasmosis, in HIV infection, 483
 resistance to, *Giardia lamblia*, 1792
- Microbicides, vaginal, safety, 476
- Microbiology
 clinical laboratories for, consolidation, Infectious Diseases Society of America policy statement on, 604, 605
 fellowship training on, adequacy of, 255
- β_2 -Microglobulin, measurement, in primary HIV infection, treatment effects, 1095
- Microsporidium* infections, practice guidelines, 331
- Minocycline, for leprosy, 930
- Mollaret's meningitis, pathology, 1589
- Molluscum contagiosum* infections, pathology, 1589
- Monkeypox, nosocomial, prevention, 446
- Monobactams, resistance to, new β -lactamases and, 1085
- Moraxella catarrhalis* infections
 pneumonia, in Finland, 1141
 resistance in
 global, S81
 trimethoprim-sulfamethoxazole, 1608
 treatment, moxifloxacin, S51
- Mortality
 in adenovirus infections, 1423
 in bone marrow transplantation, 871
 in *Aspergillus* infections, 358
 in babesiosis, 1117
 in bee sting infections, e36
 in *Candida lusitaniae* infections, 186
 in candidiasis, in cancer, 1713
 in cytomegalovirus infections, in leukemia, 539
 in diarrhea, 331
 in endocarditis, fungal, 50
 in *Enterococcus* bacteremia, 587
 in fungal infections, in bone marrow transplantation, 1319
 in HIV infection, with hepatitis C, 492, 1207
 in human immunodeficiency virus infection, 492, 1207, 1487
 in infectious complications
 bone marrow or stem cell transplantation, 391
 hip arthroplasty, 419
 in kidney failure in amphotericin B therapy, 686
 in measles, in HIV infection, e57
- in meningitis
 in African children, 64
 fever interval and, 566
- in meningococcemia, 1338
- in *Neisseria gonorrhoeae* septic shock, e92
- in *Neisseria meningitidis* infections, in pediatric patients, 1004
- in panhypopituitarism, due to infections, 153
- in penicilliosis, in HIV infection, e78
- in *Rhodococcus equi* infections, e39
- in *Staphylococcus aureus* mediastinitis, methicillin resistance and, 877
- in toxoplasmosis, in stem cell transplantation, e1
- in tuberculosis, drug-resistant, 373
- Mosquitoes, in disease transmission
 dengue hemorrhagic fever, 204, 243
 West Nile virus, 277
- Mouth (see Oral cavity)
- Moxifloxacin
 activity, S16
 clinical evaluation, S51
 respiratory pathogens, S64
 Streptococcus pneumoniae, S22
 Streptococcus pyogenes, S30
- interactions with, S47
- mechanisms of action, S9
- for penicillin-resistant *Streptococcus pneumoniae* infections, S22
- pharmacodynamics, S22, S33, S39, S47, S51
- resistance to, S1, S16, S51
- for respiratory tract infections, S64
- safety profile [letter], 1112
- side effects, S51
- toxicity, S72, 1112 [letter]
- Mucormycosis
 pathology, 1589
 treatment with granulocyte-macrophage colony-stimulating factor, e166
- Multiple organ failure syndrome
 in HIV infection, 1487
 human herpesvirus type 6 reactivation in, 197
- Muscle disorders (see also Myositis)
 in babesiosis, 1117
 in human T cell leukemia virus type 1 virus-associated myopathy, 510
- hydatidosis, treatment, e65
- necrosis, due to *Edwardsiella tarda*, 1430
- due to quinupristin-dalfopristin, e83
- rhabdomyolysis, in HIV infection, 502
- Myalgia
 in babesiosis, 1117
 due to quinupristin-dalfopristin, e83
- Mycobacterium abscessus* infections
 in cystic fibrosis, 1648
 in HIV infection, 432
 osteomyelitis, 1506
- Mycobacterium avium* complex infections
 in cystic fibrosis, 1298
 in HIV infection
 prophylaxis, 116, 1615
 treatment, e81
- in immunorestitution disease [letter and reply], 845, 846
- osteomyelitis, 1506
- respiratory, treatment, 1547
- Mycobacterium bovis* infections
 osteomyelitis, 1506
 strain B, nosocomial outbreak, 159
- Mycobacterium cheloneae* infections, in cystic fibrosis, 1298
- Mycobacterium* infections

- catheter-related, guidelines, 1249
 nontuberculous, in cystic fibrosis, 1298
 pathology, 1589
 T lymphocyte type 1/type 2 immunity in, 76
- Mycobacterium leprae* infections (see Leprosy)
Mycobacterium tuberculosis (see Tuberculosis)
 Mycophenolate mofetil, for HIV infection, 1738
Mycoplasma genitalium infections
 in HIV infection, 611
 urethritis, 995
Mycoplasma pneumoniae infections
 encephalitis, in pediatric patients, 1674
 neurologic disorders in, e31
 pneumonia
 in Finland, 1141
 in pediatric patients, 1281
 Still's disease in, e105
- Myelitis
 due to *Cryptococcus neoformans*, 1235
 transverse, in enterovirus 71 infections, 236
- Myelopathy, due to human T cell leukemia virus type 1 virus, inclusion body myositis in, 510
- Myelosuppression, in HIV infection, natural history, 469
- Myocarditis, due to *Coxiella burnetii*, 1440
- Myonecrosis, due to *Edwardsiella tarda*, 1430
- Myositis
 due to *Cryptococcus neoformans*, in hepatitis C, 1104
 inclusion body, in human T cell leukemia virus type 1 virus-associated myelopathy, 510
- Nafcillin, for intravascular catheter-related infections, 1249
- Nail(s)
 acrodermatitis continua of Happleau, 431, 505
 artificial, in health care workers
 Candida infections related to, 352
 hand cleansing methods and, 367
 disorders, due to indinavir, 140
- Nalidixic acid, for diarrhea, 331
- Nandrolone, for wasting, in HIV infection, 116
- Naproxen, for malaria, in pediatric patients, 838
- Necrosis
 avascular, bone, in HIV infection, 1221
 muscle, due to *Edwardsiella tarda*, 1430
 in spider bite, 595, 636
- Necrotizing fasciitis, due to β-hemolytic streptococci, laboratory tests for, e9
- Neisseria gonorrhoeae* infections
 diagnosis, 655
 in HIV infection, 611
 pelvic inflammatory disease, Centers for Disease Control and Prevention guidelines, 103
 resistance in
 ciprofloxacin, 1313
 fluoroquinolones, 884
 shock in, e92
 treatment, 1313
 failure, 884
- Neisseria* infections, resistance in, trimethoprim-sulfamethoxazole, 1608
- Neisseria meningitidis* infections
 bacteremia, protein C replacement in, 1338
 epidemiology, in pediatric patients, in Massachusetts, 1004
 meningitis, fever interval in, in pediatric patients, 566
 resistance in, sulfonamides, 1608
 vaccines, safety data, 1273
- Nelfinavir, for HIV infection, prophylactic, 1494
- Neonatal infections
- due to *Candida*, 1579, 1637
 systemic involvement, 1018
 due to gram-negative organisms, in intensive care unit, 220
 due to HIV, vaccination for, 801
 sepsis
 due to *Campylobacter jejuni*, e97
 due to gram-negative organisms, Current News, May 15
 due to streptococci group B, prophylaxis, Current News, May 15
- Neonates, methicillin-resistant *Staphylococcus aureus* colonization in, viridans streptococci effects on, 1399, 1408
- Nephropathy (see Kidney, dysfunction and failure)
- Neuralgia, postherpetic
 in elderly persons, 1481
 after stem cell transplantation, 1414
- Neurological disorders (see also Encephalitis; Meningitis)
 due to enterovirus 71, in pediatric patients, 236
 due to fluoroquinolones, S72
 due to *Gnathostoma spinigerum*, e154
 human T cell leukemia virus type 1 virus-associated myelopathy, 510
 due to *Mycobacterium leprae*, 930
 due to *Mycoplasma pneumoniae*, e31
 due to prions, 1726
 due to tickborne pathogens, 897
 tick paralysis, 897
 due to *Toxoplasma gondii*, in stem cell transplantation, e1
 due to *Treponema pallidum*, vs. herpes simplex virus encephalitis, 1108
- Neurological surgery, chemical meningitis after, vs. bacterial meningitis, 179
- Neurosyrphilis
 vs. herpes simplex virus encephalitis, 1108
 in HIV infection, 611
 uveitis and, 1661
- Neutropenia
Aspergillus infections in, mortality in, 358
Bacillus cereus infections in, in pediatric patients, 1456
 bacteremia in, due to *Abiotrophia*, e140
 in cancer
 bacteremia breakthrough, antifungal prophylaxis and, 1532, 1538
 breast, 546
 candidemia in, outcome, 1713
 Cryptococcus neoformans infections in, e145
 gram-negative bacteremia prediction in, 832
 treatment, in children, 36
Candida lusitaniae infections in, 186
Clostridium tertium bacteremia in, 975
 empirical antifungal therapy for [letter and reply], 320, 518
 in HIV infection
 natural history, 469
 treatment, 766
 infection detection in, procalcitonin for, 1718
 treatment, 381
- Nevirapine
 for HIV infection
 complications, 124
 ototoxicity, 1623
 resistance to, monitoring, 774
- Nipponstrongylus* infections, T lymphocyte type 1/type 2 immunity in, 76
- Nitazoxanide, for giardiasis, in HIV infection, 1792
- Nitrofurantoin, resistance to, *Enterococcus*, S133
- Nocardia asteroides* infections, endocarditis, 660
- Nocardia* infections, pathology, 1589
- Norfloxacin
 for brain abscess, due to *Streptococcus intermedius*, e131
 for diarrhea, 331
 resistance to, S1

- Nortriptyline, for herpes zoster, 1481
- Nosocomial infections (*see also* Catheter-related infections)
- due to *Acinetobacter*, resistance in, S104
 - due to adenovirus, type 7d2, in pediatric patients, 694
 - due to *Candida*
 - costs [letter], 1100
 - review, 1602
 - spinal, 352
 - diarrhea, practice guidelines, 331
 - due to gram-negative organisms, in neonatal intensive care unit, 220
 - meningitis, after neurological surgery, 179
 - due to *Mycobacterium bovis* strain B, 159
 - pneumonia, treatment, 402
 - due to prions, prevention, 1348
 - due to *Staphylococcus aureus*, colonization duration, 1393
 - due to *Stenotrophomonas maltophilia*, resistance in, S104
 - due to *Streptococcus pneumoniae*, levofloxacin-resistant, 701
 - due to zoonotic organisms, review, 446
- Nursing homes, methicillin-resistant *Staphylococcus aureus* carriage in, 1393
- Nutrition, in HIV infection, with highly active antiretroviral therapy, 1769
- Nystatin, prophylactic, in intensive care unit, 1191
- Obesity, due to HIV therapy, 1769
- Occupational disorders, meningococcal infections, in school workers, 1795
- Ochrobacterium anthropi* infections, catheter-related, guidelines, 1249
- Office management, fellowship training on, adequacy of, 255
- Ofoxacin
 - for diarrhea, 331
 - for gonorrhea, in HIV infection, 611
 - for leprosy, 930
 - for pelvic inflammatory disease, 103
 - resistance to, S1, 1162
- Opiates, for herpes zoster, 1481
- Opso-myoclonus syndrome, in enterovirus 71 infections, 236
- Optic neuritis, due to *Treponema pallidum*, 1661
- Oral cavity
- infections
 - due to *Candida*, in HIV infection, 1554
 - due to *Gongylonema*, 1378
 - due to human papillomavirus, in HIV infection, 611
 - methicillin-resistant *Staphylococcus aureus* colonization, viridans streptococci inhibition, in neonates, 1399, 1408
- Oral rehydration therapy, for diarrhea, 331
- Ornithodoros* species, review, 897
- Osler's nodes, due to *Brucella* endocarditis, 63, 149
- Osteitis, due to *Treponema pallidum*, in HIV infection, 667
- Osteomyelitis
 - due to *Salmonella*, 263
 - spinal
 - due to *Candida*, 352, 527
 - due to nontuberculous mycobacteria, 1506
 - in pediatric patients, 9
 - due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
- Ototoxicity, nucleoside analog reverse transcriptase inhibitors, 1623
- Outbreaks
- adenovirus infections, type 7d2, in pediatric patients, 694
 - cyclosporiasis, Missouri, 1010
 - diarrhea, 331
 - gram-negative infections, in neonatal intensive care unit, 220
 - influenza
 - in HIV infection, 1784
 - from imported virus, 1639
- Staphylococcus aureus* infections, methicillin-resistant, 581
- tuberculosis, multidrug-resistant, 159
- West Nile viral encephalitis, New York City, 277
- Outcome
- candidemia in cancer, 1713
 - of pneumonia management, practice guidelines effects on, 728
- Pain, in herpes zoster, 1481
- Pancreas, transplantation, human herpesvirus 6 and 7 infections in, 1357
- Pancreatitis, in HIV infection, 1487
- Panhypopituitarism, immunodeficiency in, 153
- Pantoea agglomerans* infections
 - bacteremia, venous port-related, 1776
 - resistance in, fluoroquinolones, 162
- Papanicolaou stain, for infection diagnosis, 1589
- pap* genotype, *Escherichia coli*, in urinary tract infections, 1523
- Papillomatosis, respiratory, treatment with cidofovir, e62
- Paragonimiasis, clinical features, e171
- Parainfluenza virus infections, after stem cell transplantation, 413
- Paralysis, tick, 897
- Paramomycin, for cryptosporidiosis [letter and reply], 1516, 1517
- Paraplegia, due to *Gnathostoma spinigerum*, e154
- Parasitic infections, pathology, 1589
- Paresthesia, meningococcal vaccines, 1273
- Paronychia, due to indinavir, 140
- Parvovirus B19 infections
 - in HIV infection, e122, 1361
 - renal involvement in, 167
 - thrombotic thrombocytopenic purpura-like syndrome in, 311
- Pasteurella gallinarum*, *Haemophilus aphrophilus* misidentified as [letter and reply], 987, 989
- Pathology, in infection diagnosis, 1589
- PCR (*see* Polymerase chain reaction)
- Pediatric patients (*see also* Neonatal infections)
 - adenovirus infection outbreak, type 7d2, 694
 - Bacillus cereus* infections in, in immunodeficiency, 1456
 - candidiasis in, 1579, 1637
 - catheter-related infections in, guidelines, 1249
 - Chlamydia pneumoniae* infections in, 1281
 - Chromobacterium violaceum* sepsis in, e107
 - due to hemorrhagic fever in
 - microvascular leakage in, noninvasive measurement, 243
 - treatment, 204
 - diarrhea in, practice guidelines, 331
 - enterovirus infections in, treatment with pleconaril, e13
 - enterovirus 71 infections in, neurological manifestations, 236
 - febrile neutropenia in, in cancer, treatment, 36
 - Helicobacter pylori* infections in, breast-feeding practices and, 1387
 - HIV infection, treatment, 464
 - HIV infections in
 - Streptococcus pneumoniae* infections in, 1155
 - vaccination for, 801, 1090
 - Leclercia adecarboxylata* infections in [letter], 1659
 - malaria in, treatment, 838
 - meningitis in, fever interval in, 566
 - Mycoplasma pneumoniae* infections in
 - encephalitis, 1674
 - pneumonia, 1281
 - Neisseria meningitidis* infections in, 1004
 - Pneumocystis carinii* infections in, detection, 855
 - pneumonia in, 715, 1281
 - rotavirus infections in, severity, vs. strain, 1126
 - septic bursitis in, e102
 - spinal epidural abscess in, 9
 - Streptococcus pneumoniae* colonization in, Indonesia, 1039
 - Streptococcus pneumoniae* infections in

- invasive, serogroups, 1155
 urinary assay for, 824
 tuberculosis in, diagnosis, 17
 visceral leishmaniasis in, without endemic area exposure, 302
Pelvic inflammatory disease, treatment, Centers for Disease Control and Prevention guidelines, 103
Penicillin(s)
 allergy to, skin tests for, 317, 1685
 for intravascular catheter-related infections, 1249
 resistance to
 Moraxella catarrhalis, S81
 new β-lactamases and, 1085
 Streptococcus pneumoniae, S22, S81, 972, 1044, 1463
 for syphilis, 1661
 in HIV infection, 611
 for uveitis, due to *Treponema pallidum*, 1661
Penicillin G, for Whipple's disease, 457
Penicilliosis, in HIV infection, e78, 955
Pentamidine, prophylactic, for *Mycobacterium avium* complex infections, in HIV infection, 1615
Pentoxyfylline, for chronic venous disease, 949
Periodic acid-Schiff stain, for infection diagnosis, 1589
Peripheral neuropathy, in *Mycoplasma pneumoniae* infections, e31
Pertussis
 in adults and adolescents, 1691, 1698
 epidemiology, in elderly persons [letter], 847
P fimbriae, *Escherichia coli*, in urinary tract infections, 1523
Phagocytosis, T lymphocyte type 1/type 2 immunity and, 76
Pharmacodynamics (*see also specific drug*)
 principles, practical use, S39
Pharmacokinetics, principles, practical use, S39
Pharyngitis
 due to *Neisseria gonorrhoeae*, in HIV infection, 611
 due to streptococci group A, treatment, S30, 1798
Pharynx, papillomatosis in, treatment with cidofovir, e62
Phenotyping, in drug resistance detection, in HIV infection, 774
Phototoxicity, fluoroquinolones, S72
Piperacillin, resistance to
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
Piperacillin-tazobactam, resistance to
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
 Stenotrophomonas maltophilia, S104
Pituitary insufficiency, immunodeficiency in, 153
Plague
 nosocomial, prevention, 446
 in simulated bioterrorist attack, drill for, 436
Plasmid analysis, for microorganisms in global resistance surveillance program, S156
Plasmodium falciparum malaria
 blackwater fever in, 1133
 treatment, in pediatric patients, 838
Platelet counts, in ehrlichiosis, 862
Pleconaril, for enterovirus infections, 228
 in immunodeficiency, e13
Plesiomonas infections, diarrhea, practice guidelines, 331
Plethysmography, in microvascular leakage measurement, in dengue hemorrhagic fever, 243
Pleura, *Pneumocystis carinii* infections, in HIV infection, 498
Pleurisy, due to *Paragonimus westermani*, clinical features, e171
Pneumococcal infections (*see Streptococcus pneumoniae* infections)
Pneumocystis carinii infections
 detection, in pediatric patients, 855
 in HIV infection, 955
 disseminated, 254, 300
 pneumonia, 116, 289, 955
 thoracic, 498
 tuberculosis with, 289
 pathology, 1589
 pneumonia, in HIV infection, 116, 289, 955
Pneumolysin, antibodies to, in *Streptococcus pneumoniae* infection diagnosis, 534
Pneumonia
 due to adenovirus
 in bone marrow transplantation, 871
 in Korean children, 1423
 due to *Blastomyces dermatitidis*, public health response to, in Colorado, e151
 after bone marrow or stem cell transplantation, 546
 due to *Chlamydia pneumoniae*, in pediatric patients, 1281
 due to *Coccidioides immitis*, risk factors for, 708
 due to cytomegalovirus, in leukemia, 539
 epidemiology, Finland, 1141
 etiology, in Finland, 1141
 in HIV infection
 Mycobacterium avium complex prophylaxis and, 1615
 due to *Pneumocystis carinii*, 116, 289, 955
 due to *Legionella*, treatment failure, 1562
 lung tap for, in pediatric patients, 715
 due to measles virus, in HIV infection, e57
 Medicare overcharges for, Current News, May 15
 due to *Mycoplasma pneumoniae*, in pediatric patients, 1281
 in panhypopituitarism, 153
 due to parainfluenza virus, after stem cell transplantation, treatment, 413
 due to *Pneumocystis carinii*, in HIV infection, 955
 antibiotic prophylaxis for, 116
 tuberculosis with, 289
 practice guidelines for, cost-effectiveness, 728
 due to *Staphylococcus*, resistance in, S114
 due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
 due to *Streptococcus pneumoniae*
 in HIV infection, 794
 pneumolysin antibody detection in, 534
 round mass in, 1188, 1233
 treatment, S22
 treatment
 fluoroquinolones, S39
 moxifloxacin, S22, S51, S64
 Pneumothorax, in lung tap, 715
 Podofilox, for human papillomavirus infections, 611
 Podophyllin, for human papillomavirus infections, 611
 Polarization, of T lymphocytes, 76
 Polioimmunotherapy
 eradication, Current News, May 1
 vaccination, HIV transmission hypothesis, 1068
 Polymerase chain reaction
 for *Cyclospora*, 1010
 for cytomegalovirus, 783
 for *Escherichia coli* pap genotype, 1523
 for human herpesvirus type 6, 197
 for HIV
 non-B subtype, 1227
 in poliovirus vaccine, 1068
 for infection diagnosis, 1589
 for microorganisms in global resistance surveillance program, S156
 for *Mycobacterium leprae*, 930
 for *Mycobacterium tuberculosis*, in pediatric patients, 17
 for *Mycoplasma pneumoniae*, e31, 1674
 for rotavirus, 1126

- for *Toxoplasma gondii*, e1
 for *Tropheryma whipplei*, 457
- Positron emission tomography, in fever of unknown origin, 191
- Postherpetic neuralgia
 in elderly persons, 1481
 after stem cell transplantation, 1414
- Practice guidelines (*see* Guidelines)
- Praziquantel
 for hydatidosis, thigh muscle, e65
 for *Schistosoma mansoni* infections, 1347, 1371
- Prednisolone, in T lymphocyte type 1/type 2 immunity, 76
- Prednisone, for herpes zoster, 1481
- Pregnancy
 brucellosis in, 1172
 HIV infection in, iron status and, 1496
 TT virus carriage in, 1376
- Prion infections
 clinical implications, 1726
 disinfection and sterilization for, 1348
- Probenecid, for syphilis, in HIV infection, 611
- Probiotics
Enterococcus faecium, 1381
 modern perspective, 1567, 1577
 vaginal flora and, e69
- Procalcitonin, for infection detection, in neutropenia, 1718
- Proctitis
 due to herpes simplex virus, in HIV infection, 611
 due to *Neisseria gonorrhoeae*, in HIV infection, 611
- Progesterins, in T lymphocyte type 1/type 2 immunity, 76
- Progressive multifocal leukoencephalopathy, treatment, failure, 150
- Pronase, inactivated, in cryptococcal antigen test kit, 836
- Prophylaxis (*see also* Infection control)
Campylobacter jejuni infections, safe food handling practices in, 1201
 Creutzfeldt-Jacob disease, 1348
 cytomegalovirus infections, 596
 in HIV infection, 783
 in transplantation, 742
 fungal infections, in intensive care unit, 1191
 histoplasmosis, in HIV infection, 1215
 HIV infection, postexposure, 1494
 mycobacterial infections, in cystic fibrosis, 1298
Mycobacterium avium complex infections, in HIV infection, 1615
 opportunistic infections, in HIV infection, 116
 sexually transmitted diseases, in travelers, 1063
 streptococci group B, in neonates, Current News, May 15
 tickborne diseases, 897
- Prosthetic joint infections
 hip, treatment, 419
 due to *Staphylococcus aureus*, 647
- Prosthetic valve infections, due to *Staphylococcus hemolyticus*, e100
- Protein C, for meningococcemia, 1338
- Proteus mirabilis*, resistance in, global, S94
- Protozoan infections, pathology, 1589
- Pseudomonas aeruginosa* infections
 catheter-related, guidelines, 1249
 pathology, 1589
 resistance in
 fluoroquinolones, 162
 global, S146, S156
 trimethoprim-sulfamethoxazole, 1608
- Public health (*see also* Bioterrorism)
 blastomycosis response, e151
 clinical microbiology laboratory services and, 604, 605
 infectious diarrhea, 331
 vaccine role in, 283
- Purpura
 in *Neisseria meningitidis* infections, in pediatric patients, 1004
 thrombotic thrombocytopenic syndrome resembling, in parvovirus B19 infections, 311
- Purpura fulminans, due to *Neisseria meningitidis*, protein C replacement in, 1338
- Pyelonephritis, due to *Candida*, 1602
- Pyuria, due to *Candida*, 1602
- Q fever
 myocarditis in, 1440
 nosocomial, prevention, 446
 review, 897
- Quality of life, in HIV infection, measurement, e47
- Quinine
 for babesiosis, 1117
 blackwater fever due to, 1133
- Quinolones (*see also* Fluoroquinolones; *specific drug*)
 mechanism of action of, S9
 resistance to, cross-resistance and dichotomous, S1
- Quinupristin-dalfopristin
 for intravascular catheter-related infections, 1249
 resistance in, *Enterococcus*, S133
 side effects, e83
- Rabies, nosocomial, prevention, 446
- Rash
 due to herpes zoster, 1414, 1481
 due to nevirapine, 124
 due to *Staphylococcus aureus*, 1470
- Rectal infections (*see* Anorectal infections)
- Red cell aplasia, in HIV infection, highly active antiretroviral therapy effects on, in pediatric patients, 464
- Rehabilitation, institutions for, methicillin-resistant *Staphylococcus aureus* carriage in, 1393
- Relapsing fever, review, 897
- Research, fellowship training on, adequacy of, 255
- Residency programs, in infectious disease, 752, 755
- Resistance, drug (*see* Drug resistance)
- Respiratory failure, in babesiosis, 1117
- Respiratory infections (*see also* Pneumonia; Tuberculosis)
 due to adenovirus
 in bone marrow transplantation, 871
 in Korean children, 1423
 type 7d2, outbreaks, 694
 due to *Aspergillus*
 in bone marrow transplantation, 1319
 mortality in, 358
 due to *Burkholderia pseudomallei*, in cystic fibrosis, e15
 due to *Coccidioides immitis*, risk factors for, 708
 due to *Cryptococcus neoformans*, in cancer, e145
 due to *Enterococcus*, resistance in, S133
 in Good's syndrome [letter], 323
 due to *Haemophilus influenzae*, resistance in, S81
 in HIV infection, due to *Pneumocystis carinii* and tuberculosis, 289
 due to human papillomavirus, treatment with cidofovir, e62
 due to *Moraxella catarrhalis*, resistance in, S81
 due to *Mycobacterium avium* complex, treatment, 1547
 due to *Paragonimus westermani*, clinical features, e171
 due to *Pneumocystis carinii*
 detection in immunocompetent infants, 855
 in HIV infection, 289
 due to *Pseudomonas aeruginosa*, resistance in, S146
 due to *Rhodococcus equi*, e39
 due to *Streptococcus pneumoniae*, resistance in, S81
 treatment
 fluoroquinolones, S64

- moxifloxacin for, S51
 Restriction endonuclease analysis, for microorganisms in global resistance surveillance program, S156
 Restriction fragment-length polymorphism analysis, for microorganisms in global resistance surveillance program, S156
 Retinitis
 due to *Candida*, in neonates, 1018
 due to cytomegalovirus
 in HIV infection, 815, Current News, May 1
 after stem cell transplantation, 214
 due to *Treponema pallidum*, 1661
 Retrocalcaneal bursitis, septic, in pediatric patients, e102
 Rhabdomyolysis, in HIV infection, 502
 Rheumatoid arthritis, juvenile, *Bartonella* infections in, e22
 Rheumatoid nodule, pathology, 1589
 Rhinocerebral zygomycosis, treatment with granulocyte-macrophage colony-stimulating factor, e166
Rhipicephalus species, review, 897
Rhodococcus equi infections
 diagnosis, 929, 970
 in immunocompetency, e39
 Ribavirin
 for adenovirus infections
 in bone marrow transplantation, 871
 in stem cell transplantation, 1290
 for parainfluenza virus infections, after stem cell transplantation, 413
Rickettsia infections, review, 897
Rickettsia prowazekii infections, meningitis, 979
 Rifabutin
 for *Mycobacterium avium* complex infections, 1547
 prophylactic, in HIV infection, 1615
 for tuberculosis [letters and reply], 321–323
 Rifampin
 for brucellosis, in pregnancy, 1172
 for leprosy, 930
 for *Mycobacterium avium* complex infections, 1547
 resistance to
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 for *Staphylococcus aureus* infections, vancomycin-resistant, 108
 for tuberculosis, in HIV infection, 623
 Risk factors, meningococcal infections, invasive, in school workers, 1795
 Ritonavir, for HIV infection
 ototoxicity, 1623
 resistance to, monitoring, 774
The River: A Journey to the Source of HIV and AIDS, on HIV transmission, 1068
 RNA
 HIV, non-B subtype, polymerase chain reaction in, 1227
 synthesis, fluoroquinolone effects on, S9
 Rocky Mountain spotted fever, review, 897
 Rotavirus infections, severity, vs. viral strain, 1126
 Round pneumonia, due to *Streptococcus pneumoniae*, 1188, 1233
 Safety, of vaccines, 283
Salmonella enteritidis infections, phage type 4, 890
Salmonella infections
 bacteremia, emergency room management, 559
 diarrhea
 epidemiology, 573
 practice guidelines, 331
 extraintestinal, *spv* genes in [letter and reply], 519
 nontyphoidal, review, 263
 resistance in
 global, S94
 nontyphoidal, 263
 trimethoprim-sulfamethoxazole, 1608
Salmonella typhimurium infections, T lymphocyte type 1/type 2 immunity in, 76
 Salpingitis, treatment, Centers for Disease Control and Prevention guidelines, 103
 Sandfly fever virus encephalitis, serotype Toscana, without meningitis, 1241
 Saquinavir, resistance to, monitoring, 774
 Sarcoidosis, Kaposi's sarcoma with, virus detection in, 1100
 Sarcoma, Kaposi's, sarcoidosis with, virus detection in, 1100
Scedosporium apiospermum infections, lymphadenitis in, e59
Scedosporium prolificans infections, disseminated, e158
Schistosoma japonicum infections, pathology, 1589
Schistosoma mansoni infections, brain, 1347, 1371
 Schizophrenia, toxoplasmosis in, 842
 Scintigraphy, gallium, in fever of unknown origin, 191
 Scrapie, mad cow disease and, 1726
 Seizures
 in enterovirus 71 infections, 236
 in *Mycoplasma pneumoniae* infections, e31
 in toxoplasmosis, e1
 SENTRY Antimicrobial Surveillance Program
 Acinetobacter, S104, S156
 Enterobacteriaceae, S156
 Enterococcus, S133, S156
 Escherichia coli, S94, S156
 extended-spectrum β -lactamase-producing organisms, S94, S156
 gram-negative bacteria, S156
 Haemophilus influenzae, S81
 Klebsiella pneumoniae, S94, S156
 molecular characterization integration in, S94, S156
 Moraxella catarrhalis, S81
 Proteus mirabilis, S94
 Pseudomonas aeruginosa, S146, S156
 Salmonella, S94
 Staphylococcus, S114
 Staphylococcus aureus, methicillin-resistant, S156
 Stenotrophomonas maltophilia, S104, S156
 Streptococcus pneumoniae, S81, S156
 Sepsis
 due to *Bacillus cereus*, in immunodeficiency, in pediatric patients, 1456
 after bee sting, due to *Streptococcus pyogenes*, e36
 due to *Campylobacter jejuni*, in pediatric patients, e97
 due to *Chromobacterium violaceum*, in pediatric patients, e107
 due to *Neisseria meningitidis*, protein C replacement in, 1338
 neonatal, due to gram-negative organisms, Current News, May 15
 in panhypopituitarism, 153
 Septic arthritis (see Arthritis, septic)
 Septic bursitis, in pediatric patients, e102
 Septic shock, due to *Neisseria gonorrhoeae*, e92
Serratia marcescens infections
 catheter-related, guidelines, 1249
 resistance in
 fluoroquinolones, 162
 trimethoprim-sulfamethoxazole, 1608
 Severe combined immunodeficiency, enterovirus infections in, treatment with pleconaril, e13
 Sex differences
 in fellowship training survey response, 255
 in nevirapine rash, 124
 Sexually transmitted diseases (see also specific diseases)
 in HIV infection, 611
 screening for, 808
 in travelers, 1063
 Shiga toxin, *Escherichia coli*
 diarrhea, epidemiology, 573
 testing for [letter], 1517

- Shigella infections**
 diarrhea
 epidemiology, 573
 practice guidelines, 331
 resistance in, trimethoprim-sulfamethoxazole, 1608
- Shingles**
 in elderly persons, 1481
 after stem cell transplantation, 1414
- Shock (see also Toxic shock syndrome)**
 in dengue hemorrhagic fever
 microvascular leakage in, noninvasive measurement, 243
 treatment, 204
 due to *Neisseria gonorrhoeae*, e92
- Sickle cell disease**, *Streptococcus pneumoniae* infections in, in pediatric patients, 1155
- Simian immunodeficiency virus**, in poliovirus vaccine, HIV transmission hypothesis, 1068
- Sinuses**, surgery on, chemical meningitis after, vs. bacterial meningitis, 179
- Sinusitis**
 in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
 due to *Streptococcus pneumoniae*, treatment, S22
 treatment, S51, S64
- Skin grafts**, for chronic venous disease, 949
- Skin lesions**
 due to *Alternaria*, in diabetes mellitus, 1178
 due to *Aspergillus*, mortality in, 358
 due to *Brucella* endocarditis, 63, 149
 due to *Candida*, 1579, 1637
 due to *Chromobacterium violaceum*, in pediatric patients, e107
 due to drug reaction, skip areas in, e17
 due to fluoroquinolones, S72
 due to *Fusarium*, in heart-liver transplantation, 1237
 due to herpes simplex virus, 1480, 1500
 in HIV infection, 611
 due to herpes zoster, 1481
 in HIV infection, 611, 1615, 1628
 due to human papillomavirus, in HIV infection, 611
 due to *Leishmania*, *braziliensis* vs. *guyanensis*, 1304
 due to *Mycobacterium leprae*, 930
 due to nevirapine, 124
 due to *Staphylococcus*, S114
 due to *Staphylococcus aureus*
 intracellular persistence, 1643
 in toxic shock syndrome, 1470
 in syphilis, in HIV infection, 611
 due to tickborne pathogens, 897
- Skin tests**
 for penicillin allergy, 317
 guidelines, 1685
- tuberculin, for hospital physicians, epidemiology, 1331
- Skull**, osteitis, due to *Treponema pallidum*, in HIV infection, 667
- Smoking**, coccidioidomycosis risk in, 708
- Soap**, antimicrobial, for hand cleansing, artificial fingernail colonization and, 367
- Social responsibility**, vaccine role in, 283
- Socioeconomic factors**, in *Helicobacter pylori* infection epidemiology, 1387
- Soft-tissue infections**
 in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
 due to *Staphylococcus*, resistance in, S114
- Solid-organ transplantation (see Transplantation, solid-organ; specific organs)**
- Sparfloxacin**
 mechanisms of action, S9
- pharmacodynamics, S39
 resistance to, S1
 toxicity, S72
- Spider bites**, vs. infections, 595, 636
- Spinal cord (see also Myelitis; Myopathy)**
 infections, book reviews, 1244
 medullary gnathostomiasis, e154
- Spine**
 epidural abscess, in pediatric patients, 9
 epidural lipomatosis, due to corticosteroids, e90
 osteomyelitis
 due to *Candida*, 527
 due to nontuberculous mycobacteria, 1506
 in pediatric patients, 9
 surgery on
 Candida infections after, 352
 chemical meningitis after, vs. bacterial meningitis, 179
- Spleen**
 abscess, due to *Brucella*, 1024
 disorders, due to *Campylobacter fetus*, in HIV infection, 295
- Sporotrichoid lymphangitis**, due to *Streptococcus* group A, e176
- Sporotrichosis**, pathology, 1589
- Sputum**, *Mycobacterium tuberculosis* persistence in, inhaled aminoglycosides for, 44
spv genes, in *Salmonella* infections, extraintestinal [letter and reply], 519
- Stains**, tissue, for infection diagnosis, 1589
- Staphylococcus aureus***
 bacteremia, venous port-related, 1776
 catheter-related, guidelines, 1249
 diabetic ketoacidosis in, 30
 mediastinitis, methicillin resistance and, 877
 methicillin-resistant
 colonization
 after hospital discharge, 1393
 viridans streptococci effects on, in newborns, 1399, 1408
 global status, S114, S156
 mediastinitis, 877
 outbreaks, Switzerland, 581
 pneumonia, treatment, 402
 pathology, 1589
 pneumonia
 lung tap for, 715
 methicillin-resistant (see *Staphylococcus aureus* infections, methicillin-resistant)
 prosthetic joints, 647
 resistance in
 quinolones, S1
 teicoplanin, 108
 trimethoprim-sulfamethoxazole, 1608
 vancomycin, 108
 small-colony variant, intracellular persistence, 1643
 spinal epidural abscess, in pediatric patients, 9
 toxic shock syndrome in, 1470
 nonmenstrual, e53
 treatment, fluoroquinolones, S33
- Staphylococcus epidermidis***, in vaginal flora, e69
- Staphylococcus epidermidis* infections**
 bacteremia, venous port-related, 1776
 catheter-related, guidelines, 1249
 treatment, fluoroquinolones, S33
- Staphylococcus hemolyticus* infections**, prosthetic valve endocarditis, e100
- Staphylococcus* infections**
 coagulase-negative
 bacteremia, venous port-related, 1776

- resistance in, global, S114
 hip arthroplasty, treatment, 419
 resistance in, global, S114
 Stavudine, for HIV infection
 ototoxicity, 1623
 resistance to, monitoring, 774
 Stem cell transplantation
 adenovirus infections in, 871, 1290
 in breast cancer, infections after, 546
 cytomegalovirus retinitis in, 214
 infectious complications, after 1 year, 391
 parainfluenza virus infections in, treatment, 413
 toxoplasmosis in, e1
 varicella-zoster virus infections in, predictive model for, 1414
Stenotrophomonas maltophilia infections
 bacteremia, venous port-related, 1776
 catheter-related, guidelines, 1249
 resistance in, global, S104, S156
 susceptibility testing [letter], 1656
 Sterilization, Creutzfeldt-Jacob disease prevention, 1348
 Sternotomy, mediastinitis after, due to *Staphylococcus aureus*, methicillin resistance and, 877
 Still's disease, due to *Mycoplasma pneumoniae*, e105
 Stings, insect, fatal infections after, e36
 Stomach, aspirate from, in tuberculosis diagnosis, 17
 Stool culture, in diarrhea, 331
 Streptococcal infections
 group A
 antibody dynamics in, e24
 pharyngitis, treatment, 1798
 resistance in, trimethoprim-sulfamethoxazole, 1608
 retrocalcaneal bursitis, e102
 sepsis, after bee sting, e36
 sporotrichoid lymphangitis, e176
 treatment, moxifloxacin, S30
 group B
 prophylaxis, in neonates, Current News, May 15
 spinal epidural abscess, in pediatric patients, 9
 β-hemolytic, laboratory tests for, e9
 hip arthroplasty, treatment, 419
 T lymphocyte type 1/type 2 immunity in, 76
 Streptococci
 group B, in normal vaginal flora, e69
 viridans, in methicillin-resistant *Staphylococcus aureus* colonization inhibition, in neonates, 1399, 1408
Streptococcus anginosus infections, abscess, 1511
Streptococcus constellatus infections, abscess, 1511
Streptococcus intermedius infections
 abscess, 1511
 hepatopulmonary syndrome in, e131
Streptococcus milleri group infections, abscess, 1511
Streptococcus pneumoniae
 colonization
 antibiotic-resistant, in Asian children, 1463
 in pediatric patients, Indonesia, 1039
 in vaginal flora, e69
 vancomycin tolerance, 552
Streptococcus pneumoniae infections
 bacteremia, emergency room management, 559
 diagnosis, pneumolysin antibody detection in, 534
 epidemiology, in pediatric patients, in Africa, 64
 in HIV infection, 794
 meningitis, fever interval in, in pediatric patients, 566
 pneumonia
 in Finland, 1141
 lung tap for, 715
 round mass in, 1188, 1233
 resistance in, 1039
 fluoroquinolones, S39
 global, S81, S156
 levofloxacin, 701
 multiple, 1463
 penicillin, S22, 972, 1044
 quinolones, S1
 vancomycin, 552
 treatment
 fluoroquinolones, S39
 moxifloxacin, S22, S51, S64
 urinary assay for, in pediatric patients, 824
 vaccination
 in heart transplantation, 307
 in HIV infection, 794
Streptococcus pyogenes infections (see Streptococcal infections, group A)
 Streptomycin
 for *Mycobacterium avium* complex infections, 1547
 resistance to, *Enterococcus*, S133
 for Whipple's disease, 457
 Stroke, in HIV infection, 1487
Strongyloides stercoralis infections, pathology, 1589
 Subacute sclerosing panencephalitis, in American-born adult, 173
 Sulfa-diazine, for toxoplasmosis, e1
 Sulfamethoxazole, resistance to, *Streptococcus pneumoniae*, 1039
 Sulfonamides, resistance to, 1608
 Surgery
 for chronic venous disease, 949
 for human papillomavirus infections, 611
 for osteomyelitis, due to *Candida*, 527
 Surgical infections
 due to *Candida*, 352
 meningitis, after neurological surgery, 179
 due to *Staphylococcus aureus*, methicillin resistance and, 877
 Surveillance (see also SENTRY Antimicrobial Surveillance Program),
 Haemophilus influenzae, after vaccination, 2
 Susceptibility testing (see also Drug resistance)
 Abiotrophia, e140
 moxifloxacin, *Streptococcus pyogenes*, S30
 Sydenham, Sir Thomas, on prudent skepticism [letter], 1519
 Syphilis
 in HIV infection, 611
 osteitis in, 667
 neurologic, vs. herpes simplex virus encephalitis, 1108
 pathology, 1589
 uveitis in, 1661
 Teicoplanin, resistance to, *Staphylococcus aureus*, 108
 Temafloxacin, toxicity, S72
 Tendonitis, fluoroquinolone-induced, S72
 Terrorism (see Bioterrorism)
 Testosterone
 in T lymphocyte type 1/type 2 immunity, 76
 for wasting, in HIV infection, 116
 Tetracycline(s)
 for cholera, 331
 for ehrlichiosis, 897
 resistance to, 1162
 Acinetobacter, S104
 extended-spectrum β-lactamase-producing organisms, S94
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
 Stenotrophomonas maltophilia, S104
 Streptococcus pneumoniae, S81
 Thalidomide

- for HIV infection, 1738
for leprosy, 930
- Thrombocytopenia**
in babesiosis, 1117
in ehrlichiosis, 862
in parvovirus B19 infections, 311
- Thrombosis**
in cytomegalovirus infections, 983
septic, catheter-related, 1249
- Thrombotic thrombocytopenic purpura, syndrome resembling, in parvovirus B19 infections**, 311
- Thrush, in HIV infection**, 1554
- Thymoma, in Good's syndrome, adult-onset [letter]**, 323
- Thyroxine replacement, HIV prophylactic drug interactions with**, 1635
- Ticarcillin**
for intravascular catheter-related infections, 1249
resistance to, *Acinetobacter*, S104
- Ticarcillin-clavulanate, resistance to**
Acinetobacter, S104
Stenotrophomonas maltophilia, S104
- Ticks, diseases transmitted by (see also Ehrlichiosis; Lyme disease)**
as nonspecific fever cause, 1434
review, 897
tick paralysis, 897
- T lymphocytes**
CD4
in HIV infection, 1738, 1756
in stem cell transplantation, varicella-zoster virus infection and, 1414
types, 76
- CD8
in HIV infection, 1738, 1756
in stem cell transplantation, varicella-zoster virus infection and, 1414
- deficiency, liver abscess in, due to *Fusobacterium nucleatum* [letter], 326
- helper, types, 76
- in HIV infection, 1756
immune-related therapy and, 1738
vs. iron status, 1496
- type 1/type 2 immunity in, 76
in virologic rebound, 1231
- type 1/type 2 immunity, 76
- Tobramycin**
area under inhibitory concentration curve values, S39
for intravascular catheter-related infections, 1249
resistance to, 1162
Acinetobacter, S104
extended spectrum β -lactamase-producing organisms, S94
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
- Toe(s), acrodermatitis continua of Hallopeau**, 431, 505
- Toenail disorders, due to indinavir**, 140
- Tolerance, vancomycin, in *Streptococcus pneumoniae***, 552
- Tonsillitis, due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users**, 581
- TOPOFF exercise, for bioterrorism preparation**, 436
- Topoisomerase inhibition, fluoroquinolones in**, S9
- Tosufloxacin, resistance to**, S1
- Toxic shock syndrome, nonmenstrual**
recurrent, 1470
due to staphylococci, e53
- Toxocariasis, as asthma risk factor**, e111
- Toxoplasmosis**
in schizophrenia, 842
in stem cell transplantation, e1
- Tracheobronchitis, due to adenovirus, in Korean children**, 1423
- Transferrin receptor, as HIV severity marker**, 1496
- Transfusions**
cytomegalovirus transmission in, prevention, 596
as *Streptococcus pneumoniae* infection risk, in HIV infection, 794
- Transmissible spongiform encephalopathy, prevention, disinfection and sterilization for**, 1348
- Transplantation**
Aspergillus infections in, mortality in, 358
bone marrow
adenovirus infections in, 871, 1325
aspergillosis in, e94
Candida lusitaniae infections in, 186
hemorrhagic cystitis in, 1325
infectious complications, after 1 year, 391
invasive fungal infections in, 1319
- cytomegalovirus infections in
preemptive treatment vs. prophylaxis, 742
prevention, 596
- heart, pneumococcal vaccination in, 307
- heart-liver, *Fusarium* infections in, 1237
- kidney
genitourinary tuberculosis after, 662
human herpesvirus 6 and 7 infections in, 1357
human herpesvirus 8 detection, Kaposi's sarcoma development, 1502
- liver
cytomegalovirus infections in, 742
hepatitis A vaccination in [letter], 1656
human herpesvirus 6 and 7 infections in, 1357
- pancreas, human herpesvirus 6 and 7 infections in, 1357
- solid-organ (see also specific organs)**
stem cell
adenovirus infections in, 871, 1290
in breast cancer, infections after, 546
- cytomegalovirus retinitis after, 214
infectious complications, after 1 year, 391
parainfluenza virus infections after, treatment, 413
- toxoplasmosis in, e1
- varicella-zoster virus infections after, predictive model for, 1414
- Transverse myelitis, in enterovirus 71 infections, 236
- TRAVAX database, for travel medicine information**, 757
- Traveler's diseases (see also Malaria)**
due to *Burkholderia pseudomallei*, in cystic fibrosis, e15
diarrhea, practice guidelines, 331
due to enteroaggregative *Escherichia coli*, 1706, 1710
- HIV type 1 non-B subtype, 1732
- information resources for, 757
sexually transmitted, 1063
- Treponema pallidum* infections (see Syphilis)**
- Treponemal tests, for syphilis, in HIV infection**, 611
- Trichinosis**
T lymphocyte type 1/type 2 immunity in, 76
treatment, failure, 638
- Trichloroacetic acid, for human papillomavirus infections**, 611
- Trichomoniasis**
in HIV infection, 611
screening for, 808
pathology, 1589
- Trichophyton beigelii* infections, catheter-related, guidelines**, 1249
- Trichuriasis, T lymphocyte type 1/type 2 immunity in**, 76
- Trimethoprim-sulfamethoxazole**
for brucellosis, in pregnancy, 1172
for *Chromobacterium violaceum* sepsis, e107
for diarrhea, 331
for intravascular catheter-related infections, 1249

- for melioidosis, in cystic fibrosis, e15
 prophylactic
 for histoplasmosis, in HIV infection, 1215
 for *Mycobacterium avium* complex infections, in HIV infection, 1615
 resistance to, 1162, 1608
Enterococcus, S133
 extended-spectrum β -lactamase-producing organisms, S94
Haemophilus influenzae, S81
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Streptococcus pneumoniae, S81
 for *Staphylococcus aureus* infections, vancomycin-resistant, 108
 for Whipple's disease, 457
Tropheryma whippelii infections, recent developments concerning, 457
 Tropical spastic paraparesis, inclusion body myositis in, 510
 Trovafloxacin
 for endocarditis, due to *Streptococcus pneumoniae*, 972
 pharmacodynamics, S39
 resistance to, S1
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
 Stenotrophomonas maltophilia, S104
 toxicity, S72
 TT virus, colonization, in pregnancy, 1376
 Tuberculin test, for hospital physicians, epidemiology, 1331
 Tuberculosis
 diagnosis, in pediatric patients, 17
 epidemiology, Internet resources on, 1580
 genitourinary, in transplantation, 662
 in HIV infection
 chemokine receptor expression in, 650
 multidrug-resistant, 159
 Pneumocystis carinii infection with, 289
 recurrence, 515
 in Thailand, 955
 treatment, 623
 information resources for, on Internet, 1580
 lymphadenitis in, vs. *Scedosporium apiospermum* infection, e59
 meningitis in, treatment, 643
 multidrug-resistant, 159
 nosocomial, due to *Mycobacterium bovis* strain B, 159
 pathology, 1589
 recurrence, in HIV infection, 515
 regulations on, Internet resources on, 1580
 research on, Internet resources on, 1580
 resistance in, multiple, clinical outcome, 373
 T lymphocyte type 1/type 2 immunity in, 76
 treatment, 373
 refractory, inhaled aminoglycosides in, 44
 treatment [letters and reply], 321-323
 Tubo-ovarian abscess, treatment, Centers for Disease Control and Prevention guidelines, 103
 Tularemia, review, 897
 Tumor(s), fever in, imaging studies, 191
 Typhus, epidemic, meningitis in, 979

 Ulcer(s)
 cutaneous, due to *Alternaria*, in diabetes mellitus, 1178
 venous, treatment, 949
 Unna boot, for chronic venous disease, 949
 Urea breath test, for *Helicobacter pylori*, breast-feeding practices and, 1387
Ureaplasma urealyticum infections
 in HIV infection, 611
 urethritis, 995

 Urethritis
 due to herpes simplex virus, 611
 in HIV infection, 611
 due to *Mycoplasma genitalium*, 995
 due to *Neisseria gonorrhoeae*, 611
 due to *Ureaplasma urealyticum*, 995
 Urinary tract infections
 due to adenovirus, 871
 in bone marrow or stem cell transplantation, 391, 871
 due to *Candida*, nosocomial, 1602
 diabetic ketoacidosis in, 30
 due to *Enterococcus*, resistance in, S133
 due to *Escherichia coli*, virulence factors, 1523
 due to *Mycobacterium tuberculosis*, after kidney transplantation, 662
 in panhypopituitarism, 153
 due to *Staphylococcus*, resistance in, S114
 Urine, Shiga toxin testing [letter], 1517
 Urticaria, meningococcal vaccines, 1273
 Uveitis, due to *Treponema pallidum*, 1661

 Vaccine Adverse Event Reporting System, meningococcal polysaccharide
 vaccine data from, 1273
 Vaccines and vaccination
 future of, 675
Haemophilus influenzae
 antibody measurement after, 2
 failure, 1700
 hepatitis A
 boosters, 396
 in liver transplantation [letter], 1656
 hepatitis B
 in injection drug users, e143
 in travelers, 1063
 HIV infection, in neonates, 801
 infectious diarrhea, 331
 influenza
 in HIV infection, 1784
 measles, in HIV infection, highly active antiretroviral therapy effects
 on, 1090
 meningococcal, intramuscular vs. subcutaneous, 170
Neisseria meningitidis, safety data, 1273
 pneumococci, in heart transplantation, 307
 poliomyelitis, HIV transmission hypothesis, 1068
 public health aspects of, potential of, 283
 safety, 283
 sexually transmitted diseases, 1063
Streptococcus pneumoniae, in HIV infection, 794
 therapeutic, for HIV infection, 1738, 1756
 T lymphocyte type 1/type 2 immunity and, 76
 varicella-zoster virus, for herpes zoster prevention, 1481
 Vagina
 microbicides for, safety, 476
 microflora
 normal, e69
 variation during menstrual cycle [letter], 325
 Vaginitis
 after bone marrow or stem cell transplantation, 546
 due to *Candida*, treatment with probiotics, 1567
 Valacyclovir
 for herpes simplex virus, in HIV infection, 611
 for herpes zoster, 1481
 Valganciclovir, for cytomegalovirus infections, Current News, May 1
 in HIV infection, 783
 Valvular heart disease, fungal endocarditis in, 50
 Vancomycin
 for endocarditis, due to *Streptococcus pneumoniae*, 972

- for intravascular catheter-related infections, 1249
for pneumonia, nosocomial, 402
resistance to
 enterococci, 1373
 bacteremia outcome [letter and reply], 1110, 1112
 coresistance patterns, S133
 endocarditis, 1373
 in hemodialysis, 23
 Enterococcus faecium, 1381
 Moraxella catarrhalis, S81
 Staphylococcus aureus, 108
 Streptococcus pneumoniae, 552
tolerance, in *Streptococcus pneumoniae*, 552
Varicella-zoster virus infections (*see also* Herpes zoster)
 after autologous peripheral blood progenitor cell transplantation, predictive model for, 1414
 pathology, 1589
Vasculitis
 fever in, imaging studies, 191
 in HIV infection, 1628
Venous disease, chronic, treatment, 949
Venous thrombosis, in cytomegalovirus infections, 983
Vertebrae (*see* Spine)
Vibrio cholerae infections, practice guidelines, 331
Vibrio cholerae non-serogroup O:1 infections, case studies, e117
Vidarabine, for adenovirus infections, in stem cell transplantation, 1290
Viral infections, pneumonia, lung tap for, 715
Viridans streptococci, in methicillin-resistant *Staphylococcus aureus* colonization inhibition, in neonates, 1399, 1408
Virulence factors, *Escherichia coli*, in urinary tract infections, 1523
Visceral leishmaniasis
 in HIV infection, highly active antiretroviral therapy effects on, 633
 without endemic area exposure, 302
Vision disorders, in *Mycoplasma pneumoniae* infections, e31
Warts, genital, due to human papillomavirus, in HIV infection, 611
Wasting, in HIV infection, 955
 antibiotic prophylaxis in, 116
 death from, 1487
Web (*see* Internet resources)
Weight management, in HIV infection, 1769
Western blot test
 for *Gnathostoma spinigerum*, e154
 for *Toxoplasma gondii*, in schizophrenia, 842
West Nile virus encephalitis
 outbreaks, New York City, 277
 reemergence, 675
Whipple's disease, as emerging infection, 457
Wound infections
 due to *Edwardsiella tarda*, 1430
 due to *Enterococcus*, resistance in, S133
Yersinia infections, diarrhea, practice guidelines, 331
Yersinia pestis infections
 nosocomial, prevention, 446
 in simulated bioterrorist attack, drill for, 436
Zalcitabine, for HIV infection, resistance to, monitoring, 774
Zidovudine, for HIV infection
 prophylactic, 1494
 resistance to, monitoring, 774
Ziehl-Neelsen stain, for infection diagnosis, 1589
Zinc lozenges, for colds, additive effects on [letter], 1520
Zoonoses (*see also* specific diseases)
 nosocomial, review, 446
 tickborne, review, 897
Zygomycosis
 pathology, 1589
 rhinocerebral, treatment with granulocyte-macrophage colony-stimulating factor, e166